Dual mechanism inhibitors for the treatment of disease

ABSTRACT

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.13/768,594 filed Feb. 15, 2013 which is a divisional of U.S. patentapplication Ser. No. 12/694,965, filed Jan. 27, 2010, which issued asU.S. Pat. No. 8,394,826 on Mar. 12, 2013, which claims priority to U.S.Provisional Patent Application No. 61/174,672, filed May 1, 2009, eachof which are incorporated herein by reference in their entireties.

FIELD OF THE INVENTION

The present invention relates to substituted isoquinoline amidecompounds and substituted benzamide compounds that affect the functionof kinases and the function of transporters in a cell and that areuseful as therapeutic agents or in conjunction with therapeutic agents.In particular, these compounds are useful in the treatment of diseasesand disorders of the eye, such as glaucoma, of the respiratory system,of the cardiovascular system, and for diseases characterized by abnormalgrowth, such as cancers.

BACKGROUND

A wide variety of hormones, neurotransmitters, and other biologicallyactive substances control, regulate, or adjust the functions of the bodyvia interaction with specific cellular receptors. Many of thesereceptors mediate the transmission of intracellular signals byactivating guanine nucleotide-binding proteins (G proteins) to which thereceptor is coupled. Such receptors are generically referred to asG-protein coupled receptors (GPCRs) and include, among others,adrenergic receptors, opioid receptors, cannabinoid receptors, andprostaglandin receptors. The biological effects of activating thesereceptors are not direct but are mediated by a host of intracellularproteins. The importance of these secondary proteins has only recentlybeen recognized and investigated as intervention points in diseasestates. One of the most important classes of downstream effectors is the“kinase” class.

Various kinases play important roles in the regulation of manyphysiological functions. For example, kinases have been implicated innumerous disease states including, but not limited to, cardiac disorderssuch as angina pectoris, essential hypertension, myocardial infarction,supraventricular and ventricular arrhythmias, congestive heart failure,and atherosclerosis, respiratory disorders such as asthma, chronicbronchitis, bronchospasm, emphysema, airway obstruction, rhinitis, andseasonal allergies, inflammation, rheumatoid arthritis, renal failure,and diabetes. Other conditions include chronic inflammatory boweldisease, glaucoma, hypergastrinemia, gastrointestinal indications suchas acid/peptic disorder, erosive esophagitis, gastrointestinalhypersecretion, mastocytosis, gastrointestinal reflux, peptic ulcer,pain, obesity, bulimia nervosa, depression, obsessive-compulsivedisorder, organ malformations (e.g., cardiac malformations),neurodegenerative diseases such as Parkinson's Disease and Alzheimer'sDisease, multiple sclerosis, Epstein-Barr infection, and cancer (NatureReviews Drug Discovery 2002, 1: 493-502). In other disease states, therole of kinases is only now becoming clear.

The success of the tyrosine-kinase inhibitor STI571 (Gleevec) in thetreatment of chronic myelogenous leukemia (Nature Reviews Drug Discovery2003, 2: 296-313) has spurred considerable efforts to develop otherkinase inhibitors for the treatment of a wide range of other cancers(Nature Reviews Cancer 2003, 3: 650-665). Seven additional kinaseinhibitor drugs have since been brought to market, establishing kinaseinhibitors as an important new drug class. Currently more than 100protein kinase inhibitors are in clinical development (Kinase InhibitorDrugs 2009, Wiley Press).

In view of the role that kinases have in many disease states, there isan urgent and continuing need for small molecule ligands that inhibit ormodulate the activity of kinases. Without wishing to be bound by theory,it is thought that modulation of the activity of kinases, including rhokinase (ROCK), by the compounds of the present invention is, in part,responsible for their beneficial effects.

An additional area of fruitful research in medicine is the study ofmonoamine transporters and the benefits of inhibition thereof. Monoaminetransporters (MAT) are structures in cell membranes that transportmonoamine-containing neurotransmitters into or out of cells. There areseveral distinct monoamine transporters, or MATs: the dopaminetransporter (DAT), the norepinephrine transporter (NET), and theserotonin transporter (SERT). DAT, NET, and SERT arestructurally-related, and each contains a structure of 12 trans-membranehelices. Modern antidepressants are thought to work by enhancingserotonergic, noradrenergic, or dopaminergic neurotransmission bybinding to their respective transporter, and thereby inhibitingneurotransmitter reuptake and effectively raising the concentration ofthe neurotransmitter in synapses. Examples of drugs that are thought tooperate by this mechanism include fluoxetine, a selective SERTinhibitor; reboxetine, a norepinephrine (NET) inhibitor; and bupropion,which inhibits both the NET and DAT (He, R. et al. J. Med. Chem. 2005,48: 7970-9; Blough, B. E. et al. J. Med. Chem. 2002, 45: 4029-37;Blough, B. E., et al. J. Med. Chem. 1996, 39: 4027-35; Torres, G. E., etal. Nat. Rev. Neurosci. 2003, 4: 13-25).

Glaucoma causes deterioration of the eye's optic nerve, the nervebundles that carry images from the ganglion cells of the eye to thebrain. Increased IOP is a hallmark of the most common forms of glaucoma,and this increased intraocular pressure likely damages the optic nerveand ganglion cells through multiple mechanisms. Current glaucomamedications act by reducing intraocular pressure, either by slowing theflow of aqueous humor into the eye or by improving the drainage of thisfluid from the eye. Inhibitors of rho kinase have been shown to reduceIOP in rabbits and monkeys by increasing aqueous humor drainage throughthe trabecular meshwork (Tian and Kaufman, Arch Ophthalmol 2004, 122:1171-1178; Tokushige et al., IOVS 2007, 48(7): 3216-3222). Several linesof experimental evidence indicate that modulating the activity of rhokinase within the aqueous humor outflow pathway could be beneficial forthe treatment of patients with glaucoma (Honjo et al., IOVS 2001; 42:137-144; Waki et al., Curr Eye Res 2001; 22: 470-474; Rao et al., IOVS2001; 42: 1029-1037). Considerable evidence suggests that thesympathetic nervous system plays a significant but complex role in theregulation of IOP (Nathanson, Proc. Natl. Acad. Sci. USA 1980;77(12):7420-7424). Sympathetic nerve fibers innervate the ciliaryprocess and trabecular meshwork (Ehinger, Acta Univ. Lund Sect 2 1964;20:3-23; Sears, 1975, Handbook of Physiology, Endocrinology VI. EdsAstwood E & Greep R: 553-590) and both sympathetic stimulation andlocally applied β-adrenergic agonists such as epinephrine decrease IOP(Sears, 1975, ibid; Dayson et al., J. Physiol. (London) 1951;113:389-397).

SUMMARY OF THE INVENTION

In one aspect, the may invention provide compounds according to FormulasI, II, III, IV, V, or VI, as describe below.

In other aspects, the invention may provide pharmaceutical compositions,comprising a compound according to Formula I, II, III, IV, V, or VI asdescribed below, and a carrier.

In further aspects, the invention may provide methods of treating adisease in a subject, the method comprising administering to a subjectan effective amount of a compound according to Formula I, II, III, IV,V, or VI as described below. The disease may be selected from the groupconsisting of eye disease including glaucoma and retinal diseases suchas Wet AMD Dry AMD (inflammation) and DME, bone disorder includingosteoporosis, vascular disease including cerebral vasospasm, coronaryvasospasm, hypertension, pulmonary hypertension, sudden death syndrome,angina, myocardial infarction, restenosis, stroke, hypertensive vasculardisease, heart failure, cardiac allograft vasculopathy, vein graftdisease, pulmonary disease including chronic obstructive pulmonarydisease (COPD) and asthma, neurological disorder including spinal cordinjury, Alzheimer's disease, multiple sclerosis, depression, attentiondeficit-hyperactivity disorder and neuropathic pain, neovasculardisorders and cancer, obesity, and erectile dysfunction.

In further aspects, the invention may provide methods of modulatingkinase activity, the methods comprising contacting a cell with acompound according to Formula I, II, III, IV, V, or VI as describedbelow, in an amount effective to modulate kinase activity.

In further aspects, the invention may provide methods of reducingintraocular pressure, the methods comprising contacting a cell with acompound according to Formula I, II, III, IV, V or VI as describedbelow, in an amount effective to reduce intraocular pressure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a scheme for the synthesis of compounds, including E1-E8.

FIG. 2 is a scheme for the synthesis of compounds, including E457-E466.

FIG. 3 is a scheme for the synthesis of benzamidines, E467-E476.

FIG. 4 is a scheme for the synthesis of para-aminobenzamide precursors,E477-E478, for the synthesis scheme of FIG. 3.

FIG. 5 is a scheme for the synthesis of para-aminobenzamide precursors,E479-E481, for the synthesis scheme of FIG. 3.

FIG. 6 is a scheme for the synthesis of compounds, including E8-E12.

FIG. 7 is a scheme for the synthesis of compounds, including E132-E139.

FIG. 8 is a scheme for the synthesis of compounds, including E140-E143.

FIG. 9 is a scheme for the synthesis of compounds, including E145-E148.

FIG. 10 is a scheme for the synthesis of compounds, including E197-S andE197-R.

FIG. 11 is a scheme for the synthesis of compounds, including E199-E203.

FIG. 12 is a scheme for the synthesis of compounds, including E204-E206.

FIG. 13 is a scheme for the synthesis of compounds, including E231-E241.

FIG. 14 is a scheme for the synthesis of compounds, including E249-253.

FIG. 15 is a scheme for the synthesis of compounds, including E275-E278.

FIG. 16 is a scheme for the synthesis of compounds, including E289-E290.

FIG. 17 is a scheme for the synthesis of compounds, including E300-E308.

FIG. 18 is a scheme for the synthesis of compounds, including E319-E325.

FIG. 19 is a scheme for the synthesis of compounds, including E371-E377.

FIG. 20 is a scheme for the synthesis of compounds, including E398-E404.

FIG. 21 is a general scheme for the synthesis of compounds, includingcompounds E429-E433.

DETAILED DESCRIPTION

Publications and patents are referred to throughout this disclosure. AllU.S. patents cited herein are hereby incorporated by reference. Allpercentages, ratios, and proportions used herein are percent by weightunless otherwise specified.

Amino isoquinolyl amides and amino benzamidyl amides are provided. Insome aspects, the compositions and methods for treating diseases andconditions wherein compounds that may be inhibitors of both rho kinaseand of a monoamine transporter (MAT) act to improve the disease state orcondition. One such disease may be glaucoma for which, among otherbeneficial effects, a marked reduction in intraocular pressure (IOP) maybe achieved.

DEFINITIONS

“Alkyl” refers to a saturated aliphatic hydrocarbon moiety includingstraight chain and branched chain groups. “Alkyl” may be exemplified bygroups such as methyl, ethyl, n-propyl, isopropyl, n-butyl and the like.Alkyl groups may be substituted or unsubstituted. Substituents may alsobe themselves substituted.

When substituted, the substituent group is preferably but not limited toC₁-C₄ alkyl, aryl, carbocyclyl, heterocarbocyclyl, heteroaryl, amino,cyano, halogen, alkoxy or hydroxyl. “C₁-C₄ alkyl” refers to alkyl groupscontaining one to four carbon atoms.

“Alkenyl” refers to an unsaturated aliphatic hydrocarbon moietyincluding straight chain and branched chain groups. Alkenyl moietiesmust contain at least one alkene. “Alkenyl” may be exemplified by groupssuch as ethenyl, n-propenyl, isopropenyl, n-butenyl and the like.Alkenyl groups may be substituted or unsubstituted. Substituents mayalso be themselves substituted. When substituted, the substituent groupis preferably alkyl, aryl, carbocyclyl, heterocarbocyclyl, heteroaryl,halogen or alkoxy. Substituents may also be themselves substituted.Substituents may be placed on the alkene itself and also on the adjacentmember atoms or the alkynyl moiety. “C₂-C₄ alkenyl” refers to alkenylgroups containing two to four carbon atoms.

“Alkynyl” refers to an unsaturated aliphatic hydrocarbon moietyincluding straight chain and branched chain groups. Alkynyl moietiesmust contain at least one alkyne. “Alkynyl” may be exemplified by groupssuch as ethynyl, propynyl, n-butynyl and the like. Alkynyl groups may besubstituted or unsubstituted. When substituted, the substituent group ispreferably alkyl, aryl, carbocyclyl, heterocarbocyclyl, heteroaryl,amino, cyano, halogen, alkoxyl or hydroxyl. Substituents may also bethemselves substituted. When substituted, substituents are not on thealkyne itself but on the adjacent member atoms of the alkynyl moiety.“C₂-C₄ alkynyl” refers to alkynyl groups containing two to four carbonatoms.

“Acyl” or “carbonyl” refers to the moiety —C(O)R wherein R is alkyl,alkenyl, alkynyl, aryl, heteroaryl, carbocyclic, heterocarbocyclic,C₁-C₄ alkyl aryl, or C₁-C₄ alkyl heteroaryl. C₁-C₄ alkylcarbonyl refersto a group wherein the carbonyl moiety is preceded by an alkyl chain of1-4 carbon atoms.

“Alkoxy” refers to the moiety —O—R wherein R is acyl, alkyl alkenyl,alkyl alkynyl, aryl, carbocyclic, heterocarbocyclic, heteroaryl, C₁-C₄alkyl aryl, or C₁-C₄ alkyl heteroaryl.

“Amino” refers to the moiety —NR′R′ wherein each R′ is, independently,hydrogen, amino, hydroxyl, alkoxyl, alkyl, aryl, cycloalkyl,heterocycloalkyl, heteroaryl, C₁-C₄ alkyl aryl, or C₁-C₄ alkylheteroaryl. The two R′ groups may themselves be linked to form a ring.The R′ groups may themselves be further substituted, in which case thegroup also known as guanidinyl is specifically contemplated under theterm “amino”.

“Aryl” or “aromatic ring” refers to an aromatic carbocyclic moiety.“Aryl” may be exemplified by phenyl. The aryl group may be substitutedor unsubstituted. Substituents may also be themselves substituted. Whensubstituted, the substituent group is preferably but not limited toalkoxyl, heteroaryl, acyl, carboxyl, carbonylamino, nitro, amino, cyano,halogen, or hydroxyl.

“Carboxyl” refers to the group —C(═O)O—R wherein R is chosen fromhydrogen, alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C₁-C₄alkyl aryl, or C₁-C₄ alkyl heteroaryl.

“Carbonyl” refers to the group —C(O)R wherein each R is, independently,hydrogen, alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C₁-C₄alkyl aryl, or C₁-C₄ alkyl heteroaryl.

“Carbonylamino” refers to the group —C(O)NR′R′ wherein each R′ is,independently, hydrogen, alkyl, aryl, cycloalkyl, heterocycloalkyl,heteroaryl, C₁-C₄ alkyl aryl, or C₁-C₄ alkyl heteroaryl. The two R′groups may themselves be linked to form a ring. Carbonylamino is alsoknown as an amide linkage.

“C₁-C₄ alkyl aryl” refers to C₁-C₄ alkyl groups having an arylsubstituent such that the aryl substituent is bonded through an alkylgroup. “C₁-C₄ alkyl aryl” may be exemplified by benzyl and phenethyl.

“C₁-C₄ alkyl heteroaryl” refers to C₁-C₄ alkyl groups having aheteroaryl substituent such that the heteroaryl substituent is bondedthrough an alkyl group.

“Carbocyclic group” or “cycloalkyl” means a monovalent saturated orunsaturated hydrocarbon ring. Carbocyclic groups are monocyclic, or arefused, spiro, or bridged bicyclic ring systems. Monocyclic carbocyclicgroups contain 3 to 10 carbon atoms, preferably 4 to 7 carbon atoms, andmore preferably 5 to 6 carbon atoms in the ring. Bicyclic carbocyclicgroups contain 8 to 12 carbon atoms, preferably 9 to 10 carbon atoms inthe ring. Carbocyclic groups may be substituted or unsubstituted.Substituents may also be themselves substituted. Preferred carbocyclicgroups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cyclohexenyl, and cycloheptyl. More preferred carbocyclic groups includecyclopentyl and cyclohexyl. The most preferred carbocyclic group iscyclohexyl. Carbocyclic groups are not aromatic.

“Halogen” refers to fluoro, chloro, bromo, or iodo moieties. Preferably,the halogen is fluoro, chloro, or bromo.

“Heteroaryl” or “heteroaromatic ring” refers to a monocyclic or bicyclicaromatic carbocyclic radical having one or more heteroatoms in thecarbocyclic ring. Heteroaryl may be substituted or unsubstituted. Whensubstituted, the substituents may themselves be substituted.Non-limiting examples of substituents may include aryl, C₁-C₄ alkylaryl,amino, halogen, hydroxy, cyano, nitro, carboxyl, carbonylamino, or C₁-C₄alkyl. Preferred heteroaromatic groups include tetrazoyl, triazolyl,thienyl, thiazolyl, purinyl, pyrimidyl, pyridyl, and furanyl. Morepreferred heteroaromatic groups include benzothiofuranyl, thienyl,furanyl, tetrazoyl, triazolyl, and pyridyl.

“Heteroatom” means an atom other than carbon in the ring of aheterocyclic group or a heteroaromatic group or the chain of aheterogeneous group. Preferably, heteroatoms are selected from the groupconsisting of nitrogen, sulfur, and oxygen atoms. Groups containing morethan one heteroatom may contain different heteroatoms.

“Heterocarbocyclic group” or “heterocycloalkyl” or “heterocyclic” meansa monovalent saturated or unsaturated hydrocarbon ring containing atleast one heteroatom. Heterocarbocyclic groups are monocyclic, or arefused, spiro, or bridged bicyclic ring systems. Monocyclicheterocarbocyclic groups contain 3 to 10 carbon atoms, preferably 4 to 7carbon atoms, and more preferably 5 to 6 carbon atoms in the ring.Bicyclic heterocarbocyclic groups contain 8 to 12 carbon atoms,preferably 9 to 10 carbon atoms in the ring. Heterocarbocyclic groupsmay be substituted or unsubstituted. Substituents may also be themselvessubstituted. Preferred heterocarbocyclic groups include epoxy,tetrahydrofuranyl, azacyclopentyl, azacyclohexyl, piperidyl, andhomopiperidyl. More preferred heterocarbocyclic groups include piperidyland homopiperidyl. The most preferred heterocarbocyclic group ispiperidyl. Heterocarbocyclic groups are not aromatic.

“Hydroxy” or “hydroxyl” means a chemical entity that consists of —OH.Alcohols contain hydroxy groups. Hydroxy groups may be free orprotected. An alternative name for hydroxyl is alcohol.

“Linker” means a linear chain of n member atoms where n is an integer offrom about 1 to about 4 member atoms.

“Member atom” means a carbon, nitrogen, oxygen, or sulfur atom. Memberatoms may be substituted up to their normal valence. If substitution isnot specified the substituents required for valency are hydrogen.

“Ring” means a collection of member atoms that are cyclic. Rings may becarbocyclic, aromatic, heterocyclic, or heteroaromatic, and may besubstituted or unsubstituted, and may be saturated or unsaturated. Ringjunctions with the main chain may be fused or spirocyclic. Rings may bemonocyclic or bicyclic. Rings contain at least 3 member atoms and atmost 10 member atoms. Monocyclic rings may contain 3 to 7 member atomsand bicyclic rings may contain from 8 to 12 member atoms. Bicyclic ringsthemselves may be fused or spirocyclic.

“Thioalkyl” refers to the group —S-alkyl.

“Sulfonyl” refers to the —S(O)₂R′ group wherein R′ is alkoxy, alkyl,aryl, carbocyclic, heterocarbocyclic, heteroaryl, C₁-C₄ alkyl aryl, orC₁-C₄ alkyl heteroaryl.

“Sulfonylamino” refers to the —S(O)₂NR′R′ group wherein each R′ isindependently alkyl, aryl, heteroaryl, C₁-C₄ alkyl aryl, or C₁-C₄ alkylheteroaryl.

“Pharmaceutically acceptable carrier” means a carrier that is useful forthe preparation of a pharmaceutical composition that is generallycompatible with the other ingredients of the composition, notdeleterious to the recipient, and neither biologically nor otherwiseundesirable. “A pharmaceutically acceptable carrier” includes both oneand more than one carrier. Embodiments include carriers for topical,ocular, parenteral, intravenous, intraperitoneal intramuscular,sublingual, nasal, and oral administration. “Pharmaceutically acceptablecarrier” also includes agents for preparation of aqueous dispersions andsterile powders for injection or dispersions.

“Excipient” as used herein includes physiologically compatible additivesuseful in preparation of a pharmaceutical composition. Examples ofpharmaceutically acceptable carriers and excipients can for example befound in Remington Pharmaceutical Science, 16^(th) Ed.

“Effective amount” as used herein refers to a dosage of the compounds orcompositions effective for influencing, reducing, or inhibiting theactivity of or preventing activation of a kinase or a transporterprotein. This term as used herein may also refer to an amount effectiveat bringing about a desired in vivo effect in an animal, preferably, ahuman, such as reduction in intraocular pressure.

“Administering” as used herein refers to administration of the compoundsas needed to achieve the desired effect.

“Eye disease” as used herein includes, but is not limited to, glaucoma,allergy, cancers of the eye, neurodegenerative diseases of the eye, anddry eye.

The term “disease or condition associated with kinase activity” is usedto mean a disease or condition treatable, in whole or in part, byinhibition of one or more kinases. The diseases or conditions mayinclude, but are not limited to, eye disease including glaucoma andretinal diseases such as Wet AMD Dry AMD (inflammation) and DME, ocularhypertension, bone disorder including osteoporosis, vascular diseaseincluding cerebral vasospasm, cardiovascular diseases, coronaryvasospasm, hypertension, pulmonary hypertension, sudden death syndrome,angina, myocardial infarction, restenosis, stroke, hypertensive vasculardisease, heart failure, cardiac allograft vasculopathy, vein graftdisease, pulmonary disease including chronic obstructive pulmonarydisease (COPD) and asthma, neurological disorder including spinal cordinjury, Alzheimer's disease, multiple sclerosis, depression, attentiondeficit-hyperactivity disorder and neuropathic pain, neovasculardisorders and cancer, obesity, and erectile dysfunction.

The term “controlling the disease or condition” is used to mean changingthe activity of one or more kinases to affect the disease or condition.

The term “contacting a cell” is used to mean contacting a cell in vitroor in vivo (i.e. in a subject, such as a mammal, including humans, cats,and dogs).

Compounds

In a first aspect of the invention, provided are isoquinoline amidecompounds. Compounds according to the inventions include those accordingto Formula I:

wherein R¹, R², and R³ are independently hydrogen, C₁-C₄ alkyl, aryl,C₁-C₄ alkyl aryl, C₁-C₄ alkyl heteroaryl, C₁-C₄ alkyl heterocyclyl,C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄alkoxy, C₁-C₄ sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, C₁-C₄carboxyl, or form a ring with each other or with A;wherein A is C₁-C₄ alkyl, C₁-C₄ alkyl aryl, C₁-C₄ alkyl heteroaryl, orforms a ring structure with R¹, R² or R³;wherein B is hydrogen, an aryl group, a heteroaryl group, a cycloalkylgroup, a heterocycloalkyl group, C₁-C₂₂ alkyl, C₁-C₂₂ alkyl aryl, C₁-C₂₂alkyl heteroaryl, C₂-C₂₂ alkenyl, C₂-C₂₂ alkynyl, C₁-C₂₂ carbonyl,C₁-C₂₂ carbonylamino, C₁-C₂₂ alkoxy, C₁-C₂₂ sulfonyl, C₁-C₂₂sulfonylamino, C₁-C₂₂ thioalkyl, or C₁-C₂₂ carboxyl, the stereocenterspresent, if any, being either ‘R’ or ‘S’ in configuration independently;wherein X¹, X², and X³ are, independently, hydrogen, hydroxyl, halogen,C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, amino, aminocarbonyl, nitro,cyano, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄ alkoxy, C₁-C₄sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, or C₁-C₄ carboxyl;wherein the double circle

indicates an aromatic or heteroaromatic ring; andwherein each Z is independently a bond, C₁-C₄ alkyl, heteroalkyl, or anO atom.

In Formula I, any and all of the stereocenters may be independentlyeither ‘R’ or ‘S’ in configuration.

Certain embodiments of Formula I include compounds of Formula III:

wherein R¹ and R² are independently hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylaryl, C₁-C₄ alkyl heteroaryl, C₁-C₄ alkyl heterocyclyl, or R¹ and R²together form a ring, either cycloalkyl or heterocycloalkyl;wherein R³ is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkyl aryl, C₁-C₄ alkylheteroaryl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ carbonyl, C₁-C₄carbonylamino, C₁-C₄ alkoxy, C₁-C₄ sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄thioalkyl, or C₁-C₄ carboxyl, or R³ may from a ring with itself or R¹ orR², and the stereocenters present, if any, being either ‘R’ or ‘S’ inconfiguration independently;wherein X¹, X², and X³ are, independently, hydrogen, hydroxyl, halogen,C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, amino, aminocarbonyl, nitro,cyano, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄ alkoxy, C₁-C₄sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, or C_(r) C₄ carboxyl;andwherein B is hydrogen, C₁-C₁₈ alkyl, C₁-C₁₈ alkyl aryl, C₁-C₁₈ alkylheteroaryl, C₁-C₁₈ carbonyl, C₁-C₁₈ carbonylamino, C₁-C₁₈ sulfonyl,C₁-C₁₈ sulfonylamino, or C₁-C₁₈ carboxyl, and the stereocenters present,if any, being either ‘R’ or ‘S’ in configuration independently.

Certain embodiments of Formula III include those wherein R¹, R², and R³are independently methyl or hydrogen, and wherein X¹, X², and X³ arehydrogen. In another preferred embodiment of Formula III, B is analiphatic carbonyl group. In another preferred embodiment of FormulaIII, B is a benzoic carbonyl group.

In other embodiments of Formula III, B is an aliphatic carbonyl group.In another preferred embodiment of Formula III, B is a benzoic carbonylgroup.

Certain embodiments of Formula I are compounds of Formula IV:

wherein R¹ and R² are independently hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylaryl, C₁-C₄ alkyl heteroaryl, C₁-C₄ alkyl heterocyclyl, or R¹ and R²together form a ring, either cycloalkyl or heterocyclyl;wherein R³ is a hydrogen, C₁-C₄ alkyl, C₁-C₄ alkyl aryl, C₁-C₄ alkylheteroaryl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ carbonyl, C₁-C₄carbonylamino, C₁-C₄ alkoxy, C₁-C₄ sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄thioalkyl, or C₁-C₄ carboxyl, and the stereocenters present, if any,being either ‘R’ or ‘S’ in configuration independently;wherein X¹, X², and X³ are, independently, hydrogen, hydroxyl, halogen,C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, amino, aminocarbonyl, nitro,cyano, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄ alkoxy, C₁-C₄sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, or C₁-C₄ carboxyl;wherein B is hydrogen, C₁-C₁₈ alkyl, C₁-C₁₈ alkyl aryl, C₁-C₁₈ alkylheteroaryl, C₁-C₁₈ carbonyl, C₁-C₁₈ carbonylamino, C₁-C₁₈ sulfonyl,C₁-C₁₈ sulfonylamino, or C₁-C₁₈ carboxyl, and the stereocenters present,if any, being either ‘R’ or ‘S’ in configuration independently; andwherein Z is a bond, C₁-C₄ alkyl, heteroalkyl, or an O atom.

Certain embodiments of Formula IV are those wherein R¹, R², and R³ areindependently methyl or hydrogen, and wherein X¹, X², and X³ arehydrogen.

In other embodiments of Formula IV, B is an aliphatic carbonyl group. Inother embodiments of Formula IV, B is a benzoic, pyridyl, naphthyl,benzothiophene, or thiazole carbonyl group. In other embodiments ofFormula IV, B is C₁-C₂ alkyl aryl, C₂-carbonyl, C₂-carbonyl amino,C₂-carboxyl, or C₂-hydroxyl aryl.

Benzamide compounds according to the invention may include thoserepresented by Formula II:

wherein R¹, R², and R³ are independently hydrogen, C₁-C₄ alkyl, aryl,C₁-C₄ alkyl aryl, C₁-C₄ alkyl heteroaryl, C₁-C₄ alkyl heterocyclyl,C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄alkoxy, C₁-C₄ sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, C₁-C₄carboxyl, or form a ring with each other or with A;wherein A is C₁-C₄ alkyl, or forms a ring structure with R¹, R², or R³;wherein B is hydrogen, an aryl group, a heteroaryl group, a cycloalkylgroup, a heterocycloalkyl group, C₁-C₂₂ alkyl, C₁-C₂₂ alkyl aryl, C₁-C₂₂alkyl heteroaryl, C₂-C₂₂ alkenyl, C₂-C₂₂ alkynyl, C₁-C₂₂ carbonyl,C₁-C₂₂ carbonylamino, C₁-C₂₂ alkoxy, C₁-C₂₂ sulfonyl, C₁-C₂₂sulfonylamino, C₁-C₂₂ thioalkyl, or C₁-C₂₂ carboxyl, and thestereocenters present, if any, being either ‘R’ or ‘S’ in configurationindependently;wherein X¹, X², and X³ are, independently, hydrogen, hydroxyl, halogen,C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, amino, aminocarbonyl, nitro,cyano, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄ alkoxy, C₁-C₄sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, or C₁-C₄ carboxyl;wherein the double circle

indicates an aromatic or heteroaromatic ring; andwherein each Z is independently a bond, C₁-C₄ alkyl, heteroalkyl, or anO atom.

In Formula II, any and all of the stereocenters may be independentlyeither ‘R’ or ‘S’ in configuration.

In certain embodiments of Formula II, R¹ is hydrogen or C₁-C₄ alkyl; Bis C₁-C₂₂ carbonyl; the stereocenters present, if any, are either ‘R’ or‘S’ in configuration independently; X₁, X₂, and X₃ are independentlyhydrogen or halogen; the double circle

indicates an aromatic or heteroaromatic ring; and Z is a bond, C₁-C₄alkyl, heteroalkyl, or an O atom.

Compounds according to the invention include those according to FormulaV:

wherein Z is a bond or —CH₂—; andB is an aryl group, a heteroaryl group, a cycloalkyl group, aheterocycloalkyl group, C₁-C₂₂ alkyl, C₁-C₂₂ alkyl aryl, C₁-C₂₂ alkylheteroaryl, C₂-C₂₂ alkenyl, C₂-C₂₂ alkynyl, C₁-C₂₂ carbonyl, C₁-C₂₂carbonylamino, C₁-C₂₂ alkoxy, C₁-C₂₂ sulfonyl, C₁-C₂₂ sulfonylamino,C₁-C₂₂ thioalkyl, or C₁-C₂₂ carboxyl.

Compounds according to the invention include those according to Formula(VI):

wherein R⁴ is C₁-C₄ alkyl and n is 0-3.

In some embodiments, R⁴ is methyl and n is 2.

Compounds according to the invention may include salts and solvates ofthe compounds according to Formulas I, II, III, IV, V, or VI. Whenracemates exists, each enantiomer or diastereomer may be separatelyused, or they may be combined in any proportion. Where tautomers existall possible tautomers are specifically contemplated.

Compounds according to the invention include compounds E482-E496 shownbelow:

Synthesis of Compounds

The amino isoquinoline amide or substituted benzamide compounds may besynthesized according to the general schemes shown in FIGS. 1-5.

According to the synthesis scheme in FIG. 1, ester (1) may be protectedwith the TIPS group and alkylated with bromomethylphthalimide to givecompound (3). The ester may be then hydrolyzed with LiOH*H₂O to givediacid (4) and coupled with 6-aminoisoquinoline using EDC as thecoupling agent. The amine (6) may be accomplished using hydrazine whichmay be then protected with Boc₂O to give (7). Deprotection of thehydroxyl group may be carried out with TBAF, and coupling with theappropriate acid may be achieved with EDC or using the acid chloride.Deprotection of the amine may be accomplished with HCl to give the finalamino isoquinoline amides.

As in FIG. 1, the synthesis scheme in FIG. 2 may begin by protecting2-(4-(hydroxymethyl)phenyl) acetic acid as the methyl ester and the TIPSalcohol to give E457. This methyl ester may be then alkylated withbromomethylphthalimide to give compound E459. The ester may behydrolyzed with LiOH*H₂O to give diacid E460 and coupled with6-aminoisoquinoline using EDC as the coupling agent giving compoundE461. Formation of the amine E462 may be accomplished using hydrazinewhich may be then protected with Boc₂O to give E463. Deprotection of thehydroxyl group may be carried out with TBAF, and coupling with theappropriate acid may be achieved with EDC or using the acid chloride.Deprotection of the amine may be accomplished with HCl to give the finalamino isoquinoline amides.

Benzamides may be synthesized using the procedures outlined in FIG. 2,but by substituting the para-amino benzamide of choice for the aminoisoquinoline, as shown in the synthesis scheme in FIG. 3.

The para-aminobenzamide precursors of the synthesis scheme in FIG. 3 maybe commercially-available, or may be synthesized by the generalsynthesis schemes of FIGS. 4-5.

According to FIG. 4, the appropriate acid may be converted to its acidchloride with oxalyl chloride then reacted with ammonia gas or anotheramine to give the amide. The nitro group may be reduced to the anilinewith hydrogen or another reducing agent. The aniline may be then coupledwith an appropriate acid using standard coupling procedures such as EDCand DMAP in pyridine as shown in FIG. 3.

An alternative synthetic route is outlined in the synthesis scheme ofFIG. 5. According to FIG. 5, the aniline may be coupled with anappropriate acid using standard coupling procedures such as EDC and DMAPin pyridine. The ester may be then converted to the correspondingprimary amide using formamide and NaOMe in DMF or to a substituted amideby heating with the appropriate amine in a solvent such as MeOH.

The abbreviations used in the synthetic schemes shown in the figureshave the following meanings: Boc₂O is di-tert-butyl-dicarbonate, DMAP isdimethyl aminopyridine, DMSO is Dimethyl Sulfoxide, HATU is2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate, LDA is lithium diisopropyl amide, DMF isdimethylformamide, THF is tetrahydrofuran, and EDC isN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride.

Compositions

The compounds of Formulas I-VI may be provided or formulated in acomposition. The compounds may be administered in a pharmaceuticallyacceptable formulation, such as in or with a pharmaceutically acceptablecarrier.

Compounds according to the invention may be administered in conjunctionwith one or more additional therapeutic agents. Suitable additionaltherapeutic agents may include, but are not limited to, beta blockers,alpha-agonists, carbonic anhydrase inhibitors, prostaglandin-likecompounds, miotic or cholinergic agents, or epinephrine compounds.

Beta blockers reduce the production of aqueous humor. Examples includelevobunolol (BETAGAN®), timolol (BETIMOL®, TIMOPTIC®), betaxolol(BETOPTIC®) and metipranolol (OPTIPRANOLOL®).

Alpha-agonists reduce the production of aqueous humor and increasedrainage. Examples include apraclonidine (IOPIDINE®) and brimonidine(ALPHAGAN®).

Carbonic anhydrase inhibitors reduce the production of aqueous humor.Examples include dorzolamide (TRUSOPT®) and brinzolamide (AZOPT®).

Prostaglandins and prostaglandin-like compounds increase the outflow ofaqueous humor. Examples include latanoprost (XALATAN®), bimatoprost(LUMIGAN®), and travoprost (TRAVATANT™).

Miotic or cholinergic agents increase the outflow of aqueous humor.Examples include pilocarpine (ISOPTO CARPINE®, PILOPINE®) and carbachol(ISOPTO CARBACHOL®).

Epinephrine compounds, such as dipivefrin (PROPINE®), also increase theoutflow of aqueous humor.

The additional therapeutic agent or agents may be administeredsimultaneously or sequentially with the compounds of the presentinvention. Sequential administration includes administration before orafter the compounds of the present invention. In some embodiments, theadditional therapeutic agent or agents may be administered in the samecomposition as the compounds of the present invention. In otherembodiments, there may be an interval of time between administration ofthe additional therapeutic agent and the compounds of the presentinvention.

In some embodiments, the administration of an additional therapeuticagent with a compound of the present invention may enable lower doses ofthe other therapeutic agents and/or administration at less frequentintervals.

Pharmaceutical compositions for use in accordance with the presentinvention may be formulated in a conventional manner using one or morephysiologically acceptable carriers or excipients. Thus, the compoundsand their physiologically acceptable salts and solvates may beformulated for administration by, for example, solid dosing, eyedrop, ina topical oil-based formulation, injection, inhalation (either throughthe mouth or the nose), implants, or oral, buccal, parenteral, or rectaladministration. Techniques and formulations may generally be found in“Reminington's Pharmaceutical Sciences”, (Meade Publishing Co., Easton,Pa.). Therapeutic compositions must typically be sterile and stableunder the conditions of manufacture and storage.

Compositions of the present invention may comprise a safe and effectiveamount of the subject compounds, and a pharmaceutically-acceptablecarrier. As used herein, “safe and effective amount” means an amount ofa compound sufficient to significantly induce a positive modification inthe condition to be treated, but low enough to avoid serious sideeffects (at a reasonable benefit/risk ratio), within the scope of soundmedical judgment. A safe and effective amount of a compound will varywith the particular condition being treated, the age and physicalcondition of the patient being treated, the severity of the condition,the duration of treatment, the nature of concurrent therapy, theparticular pharmaceutically-acceptable carrier utilized, and likefactors within the knowledge and expertise of the attending physician.

The route by which the compounds of the present invention (component A)will be administered and the form of the composition will dictate thetype of carrier (component B) to be used. The composition may be in avariety of forms, suitable, for example, for systemic administration(e.g., oral, rectal, nasal, sublingual, buccal, implants, or parenteral)or topical administration (e.g., dermal, pulmonary, nasal, aural,ocular, liposome delivery systems, or iontophoresis).

Carriers for systemic administration typically comprise at least one ofa) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants,f) flavors, g) sweeteners, h) antioxidants, j) preservatives, k)glidants, m) solvents, n) suspending agents, o) wetting agents, p)surfactants, combinations thereof, and others. All carriers are optionalin the systemic compositions.

Ingredient a) is a diluent. Suitable diluents for solid dosage formsinclude sugars such as glucose, lactose, dextrose, and sucrose; diolssuch as propylene glycol; calcium carbonate; sodium carbonate; sugaralcohols, such as glycerin; mannitol; and sorbitol. The amount ofingredient a) in the systemic or topical composition is typically about50 to about 90%.

Ingredient b) is a lubricant. Suitable lubricants for solid dosage formsare exemplified by solid lubricants including silica, talc, stearic acidand its magnesium salts and calcium salts, calcium sulfate; and liquidlubricants such as polyethylene glycol and vegetable oils such as peanutoil, cottonseed oil, sesame oil, olive oil, corn oil and oil oftheobroma. The amount of ingredient b) in the systemic or topicalcomposition is typically about 5 to about 10%.

Ingredient c) is a binder. Suitable binders for solid dosage formsinclude polyvinyl pyrrolidone; magnesium aluminum silicate; starchessuch as corn starch and potato starch; gelatin; tragacanth; andcellulose and its derivatives, such as sodium carboxymethylcellulose,ethyl cellulose, methylcellulose, microcrystalline cellulose, and sodiumcarboxymethylcellulose. The amount of ingredient c) in the systemiccomposition is typically about 5 to about 50%, and in ocular soliddosing forms up to 99%_(.)

Ingredient d) is a disintegrant. Suitable disintegrants for solid dosageforms include agar, alginic acid and the sodium salt thereof,effervescent mixtures, croscarmelose, crospovidone, sodium carboxymethylstarch, sodium starch glycolate, clays, and ion exchange resins. Theamount of ingredient d) in the systemic or topical composition istypically about 0.1 to about 10%.

Ingredient e) for solid dosage forms is a colorant such as an FD&C dye.When used, the amount of ingredient e) in the systemic or topicalcomposition is typically about 0.005 to about 0.1%.

Ingredient f) for solid dosage forms is a flavor such as menthol,peppermint, and fruit flavors. The amount of ingredient f), when used,in the systemic or topical composition is typically about 0.1 to about1.0%.

Ingredient g) for solid dosage forms is a sweetener such as aspartameand saccharin. The amount of ingredient g) in the systemic or topicalcomposition is typically about 0.001 to about 1%.

Ingredient h) is an antioxidant such as butylated hydroxyanisole(“BHA”), butylated hydroxytoluene (“BHT”), and vitamin E. The amount ofingredient h) in the systemic or topical composition is typically about0.1 to about 5%.

Ingredient j) is a preservative such as benzalkonium chloride, methylparaben and sodium benzoate. The amount of ingredient j) in the systemicor topical composition is typically about 0.01 to about 5%.

Ingredient k) for solid dosage forms is a glidant such as silicondioxide. The amount of ingredient k) in the systemic or topicalcomposition is typically about 1 to about 5%.

Ingredient m) is a solvent, such as water, isotonic saline, ethyloleate, glycerine, hydroxylated castor oils, alcohols such as ethanol,and phosphate buffer solutions. The amount of ingredient m) in thesystemic or topical composition is typically from about 0 to about 100%.

Ingredient n) is a suspending agent. Suitable suspending agents includeAVICEL® RC-591 (from FMC Corporation of Philadelphia, Pa.) and sodiumalginate. The amount of ingredient n) in the systemic or topicalcomposition is typically about 1 to about 8%.

Ingredient o) is a surfactant such as lecithin, Polysorbate 80, andsodium lauryl sulfate, and the TWEENS® from Atlas Powder Company ofWilmington, Del. Suitable surfactants include those disclosed in theC.T.F.A. Cosmetic Ingredient Handbook, 1992, pp. 587-592; Remington'sPharmaceutical Sciences, 15th Ed. 1975, pp. 335-337; and McCutcheon'sVolume 1, Emulsifiers & Detergents, 1994, North American Edition, pp.236-239. The amount of ingredient o) in the systemic or topicalcomposition is typically about 0.1% to about 5%.

Although the amounts of components A and B in the systemic compositionsmay vary depending on the type of systemic composition prepared, thespecific derivative selected for component A and the ingredients ofcomponent B, in general, system compositions comprise 0.01% to 50% ofcomponent A and 50% to 99.99% of component B.

Compositions for parenteral administration typically comprise A) 0.1% to10% of the compounds of the present invention and B) 90% to 99.9% of acarrier comprising a) a diluent and m) a solvent. In one embodiment,component a) comprises propylene glycol and m) comprises ethanol orethyl oleate.

Compositions for oral administration can have various dosage forms. Forexample, solid forms include tablets, capsules, granules, and bulkpowders. These oral dosage forms comprise a safe and effective amount,usually at least about 5%, and more particularly from about 25% to about50% of component A). The oral dosage compositions further comprise about50% to about 95% of component B), and more particularly, from about 50%to about 75%.

Tablets can be compressed, tablet triturates, enteric-coated,sugar-coated, film-coated, or multiple-compressed. Tablets typicallycomprise component A, and component B a carrier comprising ingredientsselected from the group consisting of a) diluents, b) lubricants, c)binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, k)glidants, and combinations thereof. Specific diluents include calciumcarbonate, sodium carbonate, mannitol, lactose and cellulose. Specificbinders include starch, gelatin, and sucrose. Specific disintegrantsinclude alginic acid and croscarmelose. Specific lubricants includemagnesium stearate, stearic acid, and talc. Specific colorants are theFD&C dyes, which can be added for appearance. Chewable tabletspreferably contain g) sweeteners such as aspartame and saccharin, or f)flavors such as menthol, peppermint, fruit flavors, or a combinationthereof.

Capsules (including implants, time release and sustained releaseformulations) typically comprise component A, and a carrier comprisingone or more a) diluents disclosed above in a capsule comprising gelatin.Granules typically comprise component A, and preferably further comprisek) glidants such as silicon dioxide to improve flow characteristics.Implants can be of the biodegradable or the non-biodegradable type.Implants may be prepared using any known biocompatible formulation.

The selection of ingredients in the carrier for oral compositionsdepends on secondary considerations like taste, cost, and shelfstability, which are not critical for the purposes of this invention.One skilled in the art would know how to select appropriate ingredientswithout undue experimentation.

The solid compositions may also be coated by conventional methods,typically with pH or time-dependent coatings, such that component A isreleased in the gastrointestinal tract in the vicinity of the desiredapplication, or at various points and times to extend the desiredaction. The coatings typically comprise one or more components selectedfrom the group consisting of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethylcellulose, EUDRAGIT® coatings (available from Rohm & Haas G.M.B.H. ofDarmstadt, Germany), waxes and shellac.

Compositions for oral administration can also have liquid forms. Forexample, suitable liquid forms include aqueous solutions, emulsions,suspensions, solutions reconstituted from non-effervescent granules,suspensions reconstituted from non-effervescent granules, effervescentpreparations reconstituted from effervescent granules, elixirs,tinctures, syrups, and the like. Liquid orally administered compositionstypically comprise component A and component B, namely, a carriercomprising ingredients selected from the group consisting of a)diluents, e) colorants, f) flavors, g) sweeteners, j) preservatives, m)solvents, n) suspending agents, and o) surfactants. Peroral liquidcompositions preferably comprise one or more ingredients selected fromthe group consisting of e) colorants, f) flavors, and g) sweeteners.

Other compositions useful for attaining systemic delivery of the subjectcompounds include sublingual, buccal and nasal dosage forms. Suchcompositions typically comprise one or more of soluble filler substancessuch as a) diluents including sucrose, sorbitol and mannitol; and c)binders such as acacia, microcrystalline cellulose, carboxymethylcellulose, and hydroxypropyl methylcellulose. Such compositions mayfurther comprise b) lubricants, e) colorants, f) flavors, g) sweeteners,h) antioxidants, and k) glidants.

In one embodiment of the invention, the compounds of the presentinvention are topically administered. Topical compositions that can beapplied locally to the eye may be in any form known in the art,non-limiting examples of which include solids, liquid drops, gelabledrops, sprays, ointments, or a sustained or non-sustained release unitplaced in the conjunctival cul-du-sac of the eye or another appropriatelocation.

Topical compositions that can be applied locally to the skin may be inany form including solids, solutions, oils, creams, ointments, gels,lotions, shampoos, leave-on and rinse-out hair conditioners, milks,cleansers, moisturizers, sprays, skin patches, and the like. Topicalcompositions comprise: component A, the compounds described above, andcomponent B, a carrier. The carrier of the topical compositionpreferably aids penetration of the compounds into the skin. Component Bmay further comprise one or more optional components.

The amount of the carrier employed in conjunction with component A issufficient to provide a practical quantity of composition foradministration per unit dose of the medicament. Techniques andcompositions for making dosage forms useful in the methods of thisinvention are described in the following references: ModernPharmaceutics, Chapters 9 and 10, Banker & Rhodes, eds. (1979);Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); andAnsel, Introduction to Pharmaceutical Dosage Forms, 2^(nd) Ed., (1976).

Component B may comprise a single ingredient or a combination of two ormore ingredients. In the topical compositions, component B comprises atopical carrier. Suitable topical carriers comprise one or moreingredients selected from the group consisting of phosphate bufferedsaline, isotonic water, deionized water, monofunctional alcohols,symmetrical alcohols, aloe vera gel, allantoin, glycerin, vitamin A andE oils, mineral oil, propylene glycol, PPG-2 myristyl propionate,dimethyl isosorbide, castor oil, combinations thereof, and the like.More particularly, carriers for skin applications include propyleneglycol, dimethyl isosorbide, and water, and even more particularly,phosphate buffered saline, isotonic water, deionized water,monofunctional alcohols, and symmetrical alcohols.

The carrier of the topical composition may further comprise one or moreingredients selected from the group consisting of q) emollients, r)propellants, s) solvents, t) humectants, u) thickeners, v) powders, w)fragrances, x) pigments, and y) preservatives.

Ingredient q) is an emollient. The amount of ingredient q) in askin-based topical composition is typically about 5% to about 95%.Suitable emollients include stearyl alcohol, glyceryl monoricinoleate,glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil,cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate,isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate,decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate,di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropylstearate, butyl stearate, polyethylene glycol, triethylene glycol,lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylatedlanolin alcohols, petroleum, mineral oil, butyl myristate, isostearicacid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyllactate, decyl oleate, myristyl myristate, and combinations thereof.Specific emollients for skin include stearyl alcohol andpolydimethylsiloxane.

Ingredient r) is a propellant. The amount of ingredient r) in thetopical composition is typically about 0% to about 95%. Suitablepropellants include propane, butane, isobutane, dimethyl ether, carbondioxide, nitrous oxide, and combinations thereof.

Ingredient s) is a solvent. The amount of ingredient s) in the topicalcomposition is typically about 0% to about 95%. Suitable solventsinclude water, ethyl alcohol, methylene chloride, isopropanol, castoroil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether,diethylene glycol monoethyl ether, dimethylsulfoxide, dimethylformamide, tetrahydrofuran, and combinations thereof. Specific solventsinclude ethyl alcohol and homotopic alcohols.

Ingredient t) is a humectant. The amount of ingredient t) in the topicalcomposition is typically 0% to 95%. Suitable humectants includeglycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, solublecollagen, dibutyl phthalate, gelatin, and combinations thereof. Specifichumectants include glycerin.

Ingredient u) is a thickener. The amount of ingredient u) in the topicalcomposition is typically about 0% to about 95%.

Ingredient v) is a powder. The amount of ingredient v) in the topicalcomposition is typically 0% to 95%. Suitable powders includebeta-cyclodextrins, hydroxypropyl cyclodextrins, chalk, talc, fullersearth, kaolin, starch, gums, colloidal silicon dioxide, sodiumpolyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammoniumsmectites, chemically-modified magnesium aluminum silicate,organically-modified Montmorillonite clay, hydrated aluminum silicate,fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose,ethylene glycol monostearate, and combinations thereof. For ocularapplications, specific powders include beta-cyclodextrin, hydroxypropylcyclodextrin, and sodium polyacrylate. For gel dosing ocularformulations, sodium polyacrylate may be used.

Ingredient w) is a fragrance. The amount of ingredient w) in the topicalcomposition is typically about 0% to about 0.5%, particularly, about0.001% to about 0.1%. For ocular applications a fragrance is nottypically used.

Ingredient x) is a pigment. Suitable pigments for skin applicationsinclude inorganic pigments, organic lake pigments, pearlescent pigments,and mixtures thereof. Inorganic pigments useful in this inventioninclude those selected from the group consisting of rutile or anatasetitanium dioxide, coded in the Color Index under the reference CI77,891; black, yellow, red and brown iron oxides, coded under referencesCI 77,499, 77,492 and, 77,491; manganese violet (CI 77,742); ultramarineblue (CI 77,007); chromium oxide (CI 77,288); chromium hydrate (CI77,289); and ferric blue (CI 77,510) and mixtures thereof.

The organic pigments and lakes useful in this invention include thoseselected from the group consisting of D&C Red No. 19 (CI 45,170), D&CRed No. 9 (CI 15,585), D&C Red No. 21 (CI 45,380), D&C Orange No. 4 (CI15,510), D&C Orange No. (CI 45,370), D&C Red No. 27 (CI 45,410), D&C RedNo. 13 (CI 15,630), D&C Red No. 7 (CI 15,850), D&C Red No. 6 (CI15,850), D&C Yellow No. 5 (CI 19,140), D&C Red No. 36 (CI 12,085), D&COrange No. 10 (CI 45,425), D&C Yellow No. 6 (CI 15,985), D&C Red No. 30(CI 73,360), D&C Red No. 3 (CI 45,430), the dye or lakes based onCochineal Carmine (CI 75,570) and mixtures thereof.

The pearlescent pigments useful in this invention include those selectedfrom the group consisting of the white pearlescent pigments such as micacoated with titanium oxide, bismuth oxychloride, colored pearlescentpigments such as titanium mica with iron oxides, titanium mica withferric blue, chromium oxide and the like, titanium mica with an organicpigment of the above-mentioned type as well as those based on bismuthoxychloride and mixtures thereof. The amount of pigment in the topicalcomposition is typically about 0% to about 10%. For ocular applicationsa pigment is generally not used.

In other certain embodiments of the invention, topical pharmaceuticalcompositions for ocular administration are prepared typically comprisingcomponent A and B (a carrier), such as purified water, and one or moreingredients selected from the group consisting of y) sugars or sugaralcohols such as dextrans, particularly mannitol and dextran 70, z)cellulose or a derivative thereof, aa) a salt, bb) disodium EDTA(Edetate disodium), and cc) a pH adjusting additive.

Examples of z) cellulose derivatives suitable for use in the topicalpharmaceutical composition for ocular administration include sodiumcarboxymethylcellulose, ethylcellulose, methylcellulose, andhydroxypropyl-methylcellulose, particularly,hydroxypropyl-methylcellulose.

Examples of aa) salts suitable for use in the topical pharmaceuticalcomposition for ocular administration include mono-, di- and trisodiumphosphate, Tris(hydroxymethyl) aminomethane hydrochloride, sodiumchloride, potassium chloride, and combinations thereof.

Examples of cc) pH adjusting additives include HCl or NaOH in amountssufficient to adjust the pH of the topical pharmaceutical compositionfor ocular administration to 5.0-7.5.

Component A may be included in kits comprising component A, a systemicor topical composition described above, or both; and information,instructions, or both that use of the kit will provide treatment forcosmetic and medical conditions in mammals (particularly humans). Theinformation and instructions may be in the form of words, pictures, orboth, and the like. In addition or in the alternative, the kit maycomprise the medicament, a composition, or both; and information,instructions, or both, regarding methods of application of medicament,or of composition, preferably with the benefit of treating or preventingcosmetic and medical conditions in mammals (e.g., humans).

Methods of Use

Compounds according to Formulas I-VI and compositions including them mayhave kinase inhibitory activity and thus may be useful in influencing orinhibiting the action of kinases, and in the treatment and/or preventionof diseases or conditions influenced by kinases. At a minimum, they mayhave NET activity and this may be useful for influencing the action ofNET. In some embodiments, methods are provided that may compriseadministering a composition comprising a specific ligand that interactsstrongly with a kinase, specifically and at minimum a rho kinase, andthat also interacts with monoamine transporter proteins (MATs),specifically and at minimum with NET proteins.

According to certain embodiments, provided are methods of influencingand/or inhibiting the action of a kinase in a cell or medium. In certainembodiments, provided are methods of influencing and/or inhibiting NETin a cell or medium. A cell may be in vitro, in a body in vivo, or in aliving body in vivo. A medium may include an assay medium. The methodsmay comprise applying to a medium or contacting a cell with an effectiveamount of a compound according to Formula I, II, III, IV, V, or VI. Themethods may comprise applying to a medium or contacting a cell withcomposition comprising an effective amount of a compound according toFormula I, II, III, IV, V, or VI, and a pharmaceutically acceptablecarrier. In some embodiments, the kinase inhibited may be a rho kinase.

According to certain embodiments, provided are methods of treating adisease, disorder, or condition. The methods may comprise administeringto a subject a compound according to Formula I, II, III, IV, V, or VI.The methods may comprise administering to a subject a compositioncomprising a compound according to Formula I, II, III, IV, V, or VI, anda pharmaceutically acceptable carrier. Diseases, disorders, orconditions may include any of the diseases or conditions associated withkinase activity or diseases or conditions affected by kinases. Forexample, the disease may be selected from the group consisting of eyedisease including glaucoma and retinal diseases such as Wet AMD Dry AMD(inflammation) and DME, bone disorder including osteoporosis, vasculardisease including cerebral vasospasm, coronary vasospasm, hypertension,pulmonary hypertension, sudden death syndrome, angina, myocardialinfarction, restenosis, stroke, hypertensive vascular disease, heartfailure, cardiac allograft vasculopathy, vein graft disease, pulmonarydisease including chronic obstructive pulmonary disease (COPD) andasthma, neurological disorder including spinal cord injury, Alzheimer'sdisease, multiple sclerosis, depression, attention deficit-hyperactivitydisorder and neuropathic pain, neovascular disorders and cancer,obesity, and erectile dysfunction. The compounds of the presentinvention may also be useful in decreasing intraocular pressure. Thus,these compounds may be useful in the treatment of glaucoma. Thepreferred route of administration for treating glaucoma is topically.

In further aspects, the invention provides methods of modulating kinaseactivity, the methods comprising contacting a cell with a compoundaccording to Formula I, II, III, IV, V, or VI as described above, in anamount effective to modulate kinase activity.

In further aspects, the invention provides methods of reducingintraocular pressure, the methods comprising contacting a cell with acompound according to Formula I, II, III, IV, V, or VI as describedabove, in an amount effective to reduce intraocular pressure.

The dosage range of the compound for systemic administration is fromabout 0.001 to about 100 mg/kg body weight, preferably from about 0.01to about 10 mg/kg per body weight, most preferably form about 0.05 toabout 5 mg/kg body weight per day. The transdermal dosages will bedesigned to attain similar serum or plasma levels, based upon techniquesknown to those skilled in the art of pharmacokinetics and transdermalformulations. Plasma levels for systemic administration are expected tobe in the range of 0.1 to 1000 ng/mL, more preferably from 0.5 to 500ng/mL and most preferably from 1 to 100 ng/mL. While these dosages arebased upon a daily administration rate, weekly or monthly accumulateddosages may also be used to calculate the clinical requirements.

Dosages may be varied based on the patient being treated, the conditionbeing treated, the severity of the condition being treated, the route ofadministration, etc. to achieve the desired effect.

The invention will be further explained by the following illustrativeexamples that are to be considered to be non-limiting.

EXAMPLES Reference Example 1

All temperatures were in degrees Centigrade. Reagents and startingmaterials were purchased from commercial sources or prepared followingpublished literature procedures.

Unless otherwise noted, HPLC purification, when appropriate, wasperformed by redissolving the compound in a small volume of DMSO andfiltering through a 0.45 micron (nylon disc) syringe filter. Thesolution was then purified using, for example, a 50 mm Varian DynamaxHPLC 21.4 mm Microsorb Guard-8 C₈ column. A typical initial elutingmixture of 40-80% MeOH:H₂O was selected as appropriate for the targetcompound. This initial gradient was maintained for 0.5 min thenincreased to 100% MeOH:0% H₂O over 5 min. 100% MeOH was maintained for 2more min before re-equilibration back to the initial starting gradient.A typical total run time was 8 min. The resulting fractions wereanalyzed, combined as appropriate, and then evaporated to providepurified material.

Proton magnetic resonance (¹H NMR) spectra were recorded on either aVarian INOVA 600 MHz (¹H) NMR spectrometer, Varian INOVA 500 MHz (¹H)NMR spectrometer, Varian Mercury 300 MHz (¹H) NMR spectrometer, or aVarian Mercury 200 MHz (¹H) NMR spectrometer. All spectra weredetermined in the solvents indicated. Although chemical shifts arereported in ppm downfield of tetramethylsilane, they are referenced tothe residual proton peak of the respective solvent peak for ¹H NMR.Interproton coupling constants are reported in Hertz (Hz).

Analytical LCMS spectra were obtained using a Waters ZQ MS ESIinstrument with an Alliance 2695 HPLC and a 2487 dual wavelength UVdetector. Spectra were analyzed at 254 and 230 nm. Samples were passedthrough a Waters Symmetry C18 4.6×75 mm 3.5 μcolumn with or without aguard column (3.9×20 mm 5μ). Gradients were run with mobile phase A:0.1% formic acid in H₂O and mobile phase B: ACN with a flow rate of 0.8mL/min. Two gradients will illustrate:

Gradient A Gradient B Time A % B % Time A % B % 0.00 80.0 20.0 0.00 95.020.0 1.00 80.0 20.0 1.00 9.0 25.0 6.00 25.0 75.0 6.00 40.0 75.0 7.00 5.095.0 7.00 5.0 95.0 8.00 5.0 95.0 8.00 5.0 95.0 9.00 80.0 20.0 9.00 95.020.0 12.00 80.0 20.0 12.00 95.0 20.0

The settings for the MS probe were a cone voltage at 38 mV and adesolvation temperature at 250° C. Any variations in these methods arenoted below.

The following preparations illustrate procedures for the preparation ofintermediates and methods for the preparation of an amino isoquinolineamide derivatives or substituted benzamide derivatives.

Examples 1-12

Compounds E1-E12 may be synthesized according to the scheme shown inFIG. 1 and FIG. 6. For example, methyl2-(4-(triisopropylsilyloxy)phenyl)acetate (E2) was synthesized from E1according to the below:

To methyl 2-(4-hydroxyphenyl)acetate (E1) in CH₂Cl₂ at 0° C. was added2,6-lutidine and TIPS-OTf. The ice bath was removed and the solution wasallowed to warm to room temperature and stirred. After 4 h the solutionwas poured into NH₄Cl_((sat)) and CH₂Cl₂ and the organic layer wasfurther extracted with NH₄Cl_((sat)). The organics were dried (Na₂SO₄)filtered and evaporated. Column chromatography (0-15% EtOAc/Hexanes)gave pure methyl-2-(4-(triisopropylsilyloxy)phenyl)acetate (E2).

Methyl 3-(1,3-dioxoisoindolin-2-yl)-2-(4-(triisopropylsilyloxy)phenyl)propanoate (E3) was prepared from E2 according to the below:

To a solution of LiHMDS in THF cooled to −78° C. was added a cooledsolution (approx −78° C.) of methyl-2-(4-(triisopropylsilyloxy)phenyl)acetate (E2) in THF via syringe. The solution was stirred at −78°C. for 30 min. Bromo-methyl phthalimide was added directly to the anion,and the solution was immediately removed from the −78° C. bath andplaced in an ice bath and stirred for 2 h. The reaction was then pouredinto NH₄Cl_((sat)) and extracted with EtOAc. The organics were dried(Na₂SO₄), filtered, and evaporated. Column chromatography 0-20%EtOAc/Hexanes gave pure methyl3-(1,3-dioxoisoindolin-2-yl)-2-(4-(triisopropylsilyloxy)phenyl)propanoate(E3).

2-(2-Carboxy-2-(4-(triisopropylsilyloxy)phenyl)ethylcarbamoyl) benzoicacid (E4) was prepared from E3 according to the below:

To methyl 3-(1,3-dioxoisoindolin-2-yl)-2-(4-(triisopropylsilyloxy)phenyl) propanoate (E3) in THF/H₂O was added LiOH.H₂O, and the solutionwas stirred for 1.5 h or until conversion to product was visible byLC-MS. The solution was then poured into EtOAc/NH₄Cl(sat)/1 N HCl (3:1),and the aqueous layer was further extracted with EtOAc. The organicswere dried (Na₂SO₄), filtered, evaporated, and dried to give crude2-(2-carboxy-2-(4-(triisopropylsilyloxy)phenyl)ethylcarbamoyl)benzoicacid (E4).

3-(1,3-Dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)-2-(4-(triisopropylsilyloxyphenyl) propanamide (E5) was prepared from E4 according to the below:

To 2-(2-carboxy-2-(4-(triisopropylsilyloxy)phenyl)ethylcarbamoyl)benzoic acid (E4) in pyridine was added EDC, DMAP, and6-aminoisoquinoline, and the solution was flushed with N₂, capped, andstirred overnight. The mixture was poured into EtOAc/NaHCO_(3(sat)) andthe aqueous layer was further extracted with EtOAc. The organics weredried (Na₂SO₄), filtered, and evaporated. Column chromatography 5%MeOH/CH₂Cl₂ gave pure3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)-2-(4-(triisopropylsilyloxyphenyl) propanamide (E5).

3-amino-N-(isoquinolin-6-yl)-2-(4-(triisopropylsilyloxy)phenyl)propanamide(E6) was prepared from E5 according to the below:

To3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)-2-(4-(triisopropylsilyloxyphenyl) propanamide (E5) in EtOH was added NH₂—NH₂, and the solution wasrefluxed for 1.2 hrs-2 hrs. The solids were filtered and the solventswere evaporated. Column chromatography 5% 2N NH₃-MeOH/CH₂Cl₂ gave pure3-amino-N-(isoquinolin-6-yl)-2-(4-(triisopropylsilyloxy)phenyl)propanamide(E6).

Tert-butyl 3-(isoquinolin-6-ylamino)-3-oxo-2-(4-(triisopropylsilyloxy)phenyl) propyl carbamate (E7) was prepared from E6 according to thebelow:

To 3-amino-N-(isoquinolin-6-yl)-2-(4-(triisopropylsilyloxy)phenyl)propanamide (E6) in CH₂Cl₂ (7.3 mL) at 0° C. was added a solutionof Boc₂O in CH₂Cl₂ also cooled to 0° C. before addition. The solutionstirred for 30 min at 0° C. and additional Boc₂O was added, and thesolution was stirred for 30 min more then poured intoCH₂Cl₂/NaHCO_(3(sat)). The aqueous layers were further extracted withCH₂Cl₂, dried (Na₂SO₄), filtered, and evaporated. Column chromatography(3% MeOH/CH₂Cl₂) gave pure tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-(triisopropylsilyloxy)phenyl)propylcarbamate (E7).

Tert-Butyl2-(4-hydroxyphenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate (E8)was prepared from E7 according to the below:

To tert-butyl 3-(isoquinolin-6-ylamino)-3-oxo-2-(4-(triisopropylsilyloxy) phenyl)propylcarbamate (E7) in THF at 0° C. was added TBAF,and the solution was stirred for 45 min at 0° C. The compound was pouredinto EtOAc and washed with NH₄Cl_((sat)), dried (Na₂SO₄), filtered, andevaporated. Column chromatography 6% MeOH/CH₂Cl₂ gave pure tert-butyl2-(4-hydroxyphenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate (E8).

4-(3-tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenylpivalate(E9) was prepared from E8 according to the below:

To tert-butyl2-(4-hydroxyphenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate (E8)in pyridine was added pivaloyl chloride, and the solution was stirredfor 2 h at room temperature. The mixture was poured into NaHCO₃ andextracted with EtOAc. The organics were dried (Na₂SO₄), filtered, andevaporated. Column chromatography 5% MeOH/CH₂Cl₂ gave pure4-(3-tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenylpivalate(E9).

4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl pivalate(E10) was prepared from E9 according to the below:

To4-(3-tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenylpivalate(E9) in CH₂Cl₂ was added HCl (4N in dioxane) and the solution wasstirred for 8-10 h. The solvents were evaporated to give pure4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl pivalate(E10).

4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl1-methylcyclopropanecarboxylate (E11) was prepared from E8 according tothe below:

To tert-butyl2-(4-hydroxyphenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate (E8)in pyridine was added EDC, DMAP, and 1-methylcyclopropanecarboxylicacid, and the solution was flushed with N₂, capped, and stirredovernight. The mixture was poured into EtOAc/NaHCO_(3(sat)) and theaqueous layer was further extracted with EtOAc. The organics were dried(Na₂SO₄), filtered, and evaporated. Column chromatography 5% MeOH/CH₂Cl₂gave pure4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl1-methylcyclopropanecarboxylate (E11).

4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl1-methylcyclopropanecarboxylate dihydrochloride (E12) was prepared fromE11 according to the below:

To4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl1-methylcyclopropanecarboxylate (E11) in CH₂Cl₂ was added HCl (4N indioxane) and the solution was stirred for 8-10 h. The solvents wereevaporated to give pure4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl1-methylcyclopropanecarboxylate dihydrochloride (E12).

Examples 13-122

Using commercially available compounds and largely the procedures setforth in Examples 2-12 and substituting the appropriate startingmaterials, the compounds E13-E91 were made and E92-E122 could besynthesized, shown in Tables 1 and 2, respectively.

TABLE 1 Compounds E13-E91.

Example R₂ R₁ 10 H -i-Pr 12 H

13 H Me 14 H t-Bu 15 H —C(CH₃)₂CH₂CH₃ 16 H —(CH₂)₆CH₃ 17 H

18 H

19 H

20 H

21 H

22 H Ph 23 H 2-MePh 24 H 3-MePh 25 H 4-MePh 26 H 2,3-diMePh 27 H2,4-diMePh 28 H 2,5-diMePh 29 H 3,4-diMePh 30 H 3,5-diMePh 31 H 2-F—Ph32 H 3-F—Ph 33 H 4-F—Ph 34 H 2-Me, 3-F—Ph 35 H 2-Me, 4-F—Ph 36 H 2-Me,5-F—Ph 37 H 4-t-BuPh 38 H 2-MeOPh 39 H 4-MeOPh 40 H 2,4-diMeOPh 41 H2-MeO, 4-MePh 42 H 2-MeO-5-MePh 43 H 3,4-O—CH₂—O—Ph 44 H 3-PhOPh 45 H—CH₂-2-MeOPh 46 H 2-NH₂—Ph 47 H 3-NH₂—Ph 48 H 4-NH₂—Ph 49 H 3-N(Me₂)—Ph50 H 4-N(Me₂)—Ph 51 H 2-CN—Ph 52 H 4-CN—Ph 53 H 4-(CH₂NH₂)—Ph 54 H2-CF₃—Ph 55 H 2-pyridyl 56 H 3-pyridyl 57 H 4-pyridyl 58 H2-Me-3-pyridyl 59 H 2-Ph—Ph 60 H 3-(COPh)—Ph 61 H

62 H

63 H —CH₂NH₂ 64 H —CH(Ph)CH₂NH₂ 65 H

66 H

67 H

68 H

69 H —Bn 70 H 4-(CH₂NMe₂)—Ph 71 H

72 H —CH(Me)Ph 73 H —CH₂-3,4-diMeOPh 74 H —CH₂CH₂Ph 75 H —CH₂CH₂CH₂Ph 76H —CH₂-2-MePh 77 H —CH₂-3-MePh 78 H —CH₂-4-MePh 79 H

80 H

81 H

82 H —CH2-4-FPh 83 H —CH₂CO₂tBu 84 H —CHEtPh 85 H —(CH₂)₁₀CH₃ 86 H—(CH₂)₇(Z)CH═CH(CH₂)₇CH₃ 87 H

88 H —CH₂CH₂CO₂Me 89 H -(E)CH═CHCO₂Me 90 H

91 H -3-MeOPh

TABLE 2 Compounds E92-E122.

Example R₂ R₁ 92 Me Me 93 Me

94 Me

95 Me Ph 96 Me 2-MePh 97 Et 2,5-diMePh 98 Et 3,4-diMePh 99 Et 2-Me,3-F—Ph 100 Et 2-Me, 4-F—Ph 101 Propyl 2-MeOPh 102 Et 2,4-diMeOPh 103 Me3,4-O—CH₂—O— 104 Allyl 2-NH₂—Ph 105 Allyl 3-NH₂—Ph 106 H —CH₂NH₂ 107 Me—CH(Ph)CH₂NH₂ 108 Propyl —CH(Ph)CH₂NH₂ 109 Et —CH(Ph)CH₂NH₂ 110 Me Bn111 Et Bn 112 Allyl Bn 113 Me

114 Me —CH(Me)Ph 115 Et —CH(Me)Ph 116 Propyl —CH(Me)Ph 117 Me —CH₂CH₂Ph118 Et —CH₂CH₂CH₂Ph 119 Me —CH₂-2-MePh 120 Me —CH₂-3-MePh 121 Me—CH(Et)Ph 122 Me

Examples 123-131

Using commercially available compounds and largely the procedures setforth in Examples 2-12 and substituting the appropriate startingmaterials, the compounds E123-E131 were made, shown in Table 3.

TABLE 3 Compounds E123-E131.

E123

E124

E125

E126

E127

E128

E129

E130

E131

Examples 132-139

Compounds E132-E139 were prepared according to the scheme in FIG. 7.

Methyl 2-(4-(hydroxymethyl)phenyl)acetate (E132) was prepared accordingto the below:

To 2-(4-(hydroxymethyl)phenyl)acetic acid in MeOH at 0° C. was addedTMS-CHN₂. The solution was stirred for 3 h then quenched with a fewdrops of AcOH. The solvents were evaporated. Column chromatography(SiO₂, 3-15% EtOAc/Hex) gave pure methyl2-(4-(hydroxymethyl)phenyl)acetate (E132).

Methyl 2-(4-((triisopropylsilyloxy)methyl) phenyl)acetate (E133) wasprepared from E132 according to the below:

To methyl 2-(4-(hydroxymethyl)phenyl)acetate (E132) in CH₂Cl₂ at 0° C.was added 2,6-lutidine and TIPS-OTf. The ice bath was removed and thesolution was allowed to warm to room temperature and stir. After 4 h thesolution was poured into NH₄Cl(sat) and CH₂Cl₂ and the organic layer wasfurther extracted with NH₄Cl(sat). The organics were dried (MgSO₄)filtered and evaporated. Column chromatography (SiO₂, 0-15%EtOAc/Hexanes) gave pure methyl2-(4-((triisopropylsilyloxy)methyl)phenyl)acetate (E133).

Methyl3-(1,3-dioxoisoindolin-2-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E134) was prepared from E133 according to the below:

To a solution of LiHMDS in THF cooled to −78° C. was added a cooledsolution (−78° C.) of methyl 2-(4-((triisopropylsilyloxy)methyl)phenyl)acetate (E133) in THF via syringe. The solution wasstirred at −78° C. for 30 min. Bromo-methyl phthalimide was addeddirectly to the anion and the solution stirred for 2 h at −78° C. Thereaction was then poured into NH₄Cl(sat) and extracted with EtOAc. Theorganics were dried (MgSO₄), filtered, and evaporated. Columnchromatography (SiO₂, 0-20% EtOAc/Hexanes) gave pure methyl3-(1,3-dioxoisoindolin-2-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate (E134).

2-(2-carboxy-2-(4-((triisopropylsilyloxy) methyl)phenyl)ethylcarbamoyl)benzoic acid (E135) was prepared from E134 according tothe below:

To methyl3-(1,3-dioxoisoindolin-2-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E134) in THF/H₂O was added LiOH.H₂O, and the solution was stirred for1.5 h or until conversion to product was visible by LC-MS. The solutionwas then poured into EtOAc/NH₄Cl(sat)/1 N HCl (3:1) and the aqueouslayer was further extracted with EtOAc. The organics were dried (MgSO₄),filtered, and evaporated to give crude2-(2-carboxy-2-(4-((triisopropylsilyloxy)methyl)phenyl)ethylcarbamoyl)benzoicacid (E135).

3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanamide(E136) was prepared from E135 according to the below:

To2-(2-carboxy-2-(4-((triisopropylsilyloxy)methyl)phenyl)ethylcarbamoyl)benzoicacid (E135) in pyridine was added EDC, DMAP and 6-aminoisoquinoline andthe solution was flushed with N₂, capped, and stirred overnight. Themixture was poured into EtOAc/NaHCO₃(sat) and the aqueous layer wasfurther extracted with EtOAc. The organics were dried (MgSO₄), filtered,and evaporated. Column chromatography (SiO₂, 5% MeOH/CH₂Cl₂) gave pure3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanamide(E136).

3-amino-N-(isoquinolin-6-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanamide(E137) was prepared from E136 according to the below:

To3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanamide(E136) in EtOH was added NH₂—NH₂ and the solution was refluxed for 1.2-2h. The solids were filtered, and the solvents were evaporated. Columnchromatography (SiO₂, 5% 2N NH₃-MeOH/CH₂Cl₂) gave pure3-amino-N-(isoquinolin-6-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanamide(E137).

Tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-((triisopropylsilyloxy)methyl)phenyl)propylcarbamate(E138) was prepared from E137 according to the below:

To3-amino-N-(isoquinolin-6-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanamide(E137) in CH₂Cl₂ at 0° C. was added a solution of Boc₂O in CH₂Cl₂ alsocooled to 0° C. before addition. The solution was stirred for 30 min at0° C. and additional Boc₂O was added and the solution was stirred for 30min more then poured into CH₂Cl₂/NaHCO₃(sat). The aqueous layers werefurther extracted with CH₂Cl₂, dried (MgSO₄), filtered, and evaporated.Column chromatography (SiO₂, 3% MeOH/CH₂Cl₂) gave tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-((triisopropylsilyloxy)methyl)phenyl)propylcarbamate(E138).

Tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E139).

To tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-((triisopropylsilyloxy)methyl)phenyl)propylcarbamate(E138) in THF at 0° C. was added TBAF, and the solution was stirred for45 min at 0° C. The compound was poured into EtOAc and washed withNH₄Cl(sat), dried (MgSO₄), filtered, and evaporated. Columnchromatography (SiO₂, 6% MeOH/CH₂Cl₂) gave pure tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E139).

Examples 140-143

Compounds E140-E143 were prepared according to the scheme in FIG. 8.

4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2-methylbenzoate (E140) was prepared from E139 according to the below:

To tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E139) in pyridine was added 2-methylbenzoyl chloride and the solutionwas stirred for 2 h at room temperature. The mixture was poured intoNaHCO₃ and extracted with EtOAc. The organics were dried (MgSO₄),filtered, and evaporated. Column chromatography (SiO₂, 5% MeOH/CH₂Cl₂)gave pure4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2-methylbenzoate (E140).

4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2-methylbenzoate dihydrochloride (E141) was prepared from E140 accordingto the below:

To4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2-methylbenzoate (E140) in CH₂Cl₂ was added HCl (4N in dioxane) and thesolution was stirred for 8-10 h. The solvents were evaporated to givepure 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2-methylbenzoate dihydrochloride (E141).

4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylcyclohexanecarboxylate (E142) was prepared from E139 according to thebelow:

To tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E139) in pyridine was added EDC, DMAP, and cyclohexanecarboxylic acid,and the solution was flushed with N₂, capped, and stirred overnight. Themixture was poured into EtOAc/NaHCO_(3(sat)) and the aqueous layer wasfurther extracted with EtOAc. The organics were dried (MgSO₄), filtered,and evaporated. Column chromatography (SiO₂, 5% MeOH/CH₂Cl₂) gave pure4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylcyclohexanecarboxylate (E142).

4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylcyclohexanecarboxylate dihydrochloride (E143) was prepared from E142according to the below:

To4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylcyclohexanecarboxylate (E142) in CH₂Cl₂ was added HCl (4 N in dioxane)and the solution was stirred for 8-10 h. The solvents were evaporated togive pure 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylcyclohexanecarboxylate dihydrochloride (E143).

Example 144

3-amino-2-(4-(hydroxymethyl)phenyl)-N-(isoquinolin-6-yl)propanamidedihydrochloride (E144) was prepared from E139 according to the below:

To tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E139) in THF and water and cooled to 0° C. was added HCl (1 N in Et₂O).After 30 min the mixture was warmed to room temperature and the solutionwas stirred for 48 h. 2 M NH₃ in MeOH was added. The solvents wereevaporated and the mixture purified by column chromatography (SiO₂,O-5-10% (2 M NH₃ in MeOH)/CH₂Cl₂). The compound was dissolved inDCM/MeOH and 1 N HCl in Et₂O added. The solvents were evaporated to givepure 3-amino-2-(4-(hydroxymethyl)phenyl)-N-(isoquinolin-6-yl)propanamidedihydrochloride (E144).

Examples 145-148

Compounds E145-E148 were prepared according to the scheme in FIG. 9.

4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E145) was prepared E139 according to the below:

To 2,4-dimethylbenzoic acid in pyridine was added EDC, DMAP, andtert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E139), and the solution was capped and stirred overnight. The mixturewas poured into EtOAc/NaHCO_(3(sat)) and the aqueous layer was furtherextracted with EtOAc. The organics were dried (MgSO₄), filtered, andevaporated. Column chromatography (SiO₂, 0-5% MeOH/CH₂Cl₂ gradient) gavepure4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E145).

4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate dihydrochloride (E146) was prepared from E145according to the below:

To4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E145) in CH₂Cl₂ was added HCl (4 N in dioxane) andthe solution was stirred for 8-10 h. The solvents were evaporated togive pure 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate dihydrochloride (E146).

4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylbutyrate (E148) was prepared from E139 according to the below:

To butyric acid in pyridine was added EDC, DMAP, and tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E139), and the solution was capped and stirred overnight. The mixturewas poured into EtOAc/NaHCO_(3(sat)) and the aqueous layer was furtherextracted with EtOAc. The organics were dried (MgSO₄), filtered, andevaporated. Column chromatography (SiO₂, 0-5% MeOH/CH₂Cl₂ gradient) gavepure4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylbutyrate (E148).

4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl butyratedihydrochloride (E148) was prepared from E147 according to the below:

To4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylbutyrate (E147) in CH₂Cl₂ was added HCl (4 N in dioxane) and thesolution was stirred for 8-10 h The solvents were evaporated to givepure 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzylbutyrateate dihydrochloride (E148).

Examples 149-175

Using commercially available compounds and largely the procedures setforth in Examples 140-143 and substituting the appropriate startingmaterials, the compounds E149-E175 have been made, shown in Table 4.

TABLE 4 Compounds E149-E175.

Example R 149

150 -iPr 151 -tBu 152 —(CH₂)₆CH₃ 153

154

155

156 —Ph 157 —Bn 158 —CH₂CH₂Ph 159 —CH₂—OPh 160

161 3,5-diMePh 162

163 —(CH₂)₁₀CH₃ 164

165 3-MeOPh 166 4-MeOPh 167 2,4-diOMePh 168 3,4-O—CH₂—O—Ph 169

170 —CHPh₂ 171 2-Ph—Ph 172

173

174

175

Examples 176-196

Using commercially available compounds and largely the procedures setforth in Examples 140-143 and substituting the appropriate startingmaterials, the compounds E176-E196, could be made, shown in Table 5.

TABLE 5 Compounds E176-E196.

Example R 176 2-MeOPh 177 4-NHMePh 178 4-NMe₂Ph 179 4-OEtPh 180 3-MePh181 4-MePh 182 2,3-diMePh 183 2,6-MePh 184 3,4-MePh 185

186 2-ClPh 187 3-ClPh 188 4-ClPh 189 2-FPh 190 3-FPh 191 4-FPh 1922,4-diClPh 193 2,4-diFPh 194

195

196

Example 197

(S)-4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E145-S) and(R)-4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E145-R) were prepared from E145 according to thescheme in FIG. 10.4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate was dissolve in methanol and the R and Senantiomers separated by supercritical fluid chromatography (ChiralpakAS-H column, eluent: 18.8% MeOH, 0.2% dimethylethylamine, 80% CO₂). Theenantiomers were then each purified by column chromotagraphy (SiO₂, 0-5%MeOH/CH₂Cl₂ gradient). The enantiomeric excess for each enantiomer was>98%.

(S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate dihydrochloride (E197-S) was prepared from E145-Saccording to the scheme in FIG. 6. To(S)-4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E145-S) in CH₂Cl₂ was added HCl (4 N in dioxane)and the solution was stirred for 8-10 h. The solvents were evaporated togive pure(S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate dihydrochloride (E197-S). Analysis by chiral HPLC(Chiralpak AS-H, eluent: 90:10:0.1 EtOH:H₂O:diethylamine) showedenantiomeric excess >98%.

(R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate dihydrochloride (E197-R) was prepared from E145-Raccording to the scheme in FIG. 6. To(S)-4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E145-R) in CH₂Cl₂ was added HCl (4 N in dioxane)and the solution was stirred for 8-10 h. The solvents were evaporated togive pure(R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate dihydrochloride (E197-R). Analysis by chiral HPLC(Chiralpak AS-H, eluent: 90:10:0.1 EtOH:H₂O:diethylamine) showedenantiomeric excess >98%.

Examples 198-203

Compounds E199-E203 were prepared according to the scheme in FIG. 11.

(4-iodobenzyloxy)triisopropylsilane (E199) was prepared from E198according to the below:

To a solution of (4-iodophenyl)methanol (E198) and imidazole in CH₂Cl₂at 0° C. was added dropwise TIPSCl. The reaction mixture was stirredovernight. The solution was quenched with H₂O and the CH₂Cl₂ layerseparated. The organic layer was further washed with 0.5N HCl andNaHCO_(3(sat)). The combined organic layers were dried (MgSO₄),filtered, and evaporated. The crude yellow oil,(4-iodobenzyloxy)triisopropylsilane (E199), was used directly in thenext step.

Ethyl 2-cyano-2-(4-((triisopropylsilyloxy)methyl)phenyl)acetate (E200)was prepared from E199 according to the below:

To a solution of ethyl 2-cyanoacetate and(4-iodobenzyloxy)triisopropylsilane (E199) in dioxane were added Cs₂CO₃,CuI, and picolinic acid. The mixture was stirred overnight at 90° C. Thesolid was removed by filtration and the dioxane concentrated underreduced pressure. Column chromatography (SiO₂, hexane:ethyl acetate25:1) gave pure ethyl2-cyano-2-(4-((triisopropylsilyloxy)methyl)phenyl)acetate (E200) as ayellow oil.

Ethyl 3-amino-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E201) was prepared from E200 according to the below:

To a suspension of CoCl₂.6H₂O in THF was added ethyl2-cyano-2-(4-((triisopropylsilyloxy)methyl)phenyl)acetate (E200). Themixture was cooled to 0° C. and NaBH₄ was added to the mixture inseveral portions over 30 min. The mixture was stirred at roomtemperature for 4 h. The reaction was quenched with water. The mixturewas filtered and the filtrate extracted twice with ether. The organicswere dried (MgSO₄), filtered, and evaporated. Column chromatography(SiO₂, DCM:EtOH=50:1) gave pure ethyl3-amino-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate (E201) as ayellow oil.

Ethyl3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E202) was prepared from E201 according to the below:

To a solution of ethyl3-amino-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate (E201) inDCM was added (Boc)₂O and triethylamine. The mixture was stirred for 2h, then washed with 0.5 N HCl and NaHCO_(3(sat)). The organic layer wasdried (MgSO₄) and concentrated to give ethyl3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E202).

3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoicacid (E203) was prepared from E202 according to the below:

To a solution of ethyl3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E202) in methanol was added dropwise 4 N NaOH. The mixture was stirredfor 2 h, adjusted the pH to 7 with 2 N HCl, and extracted with ethylacetate. The combined organic layers were washed with 0.5 N HCl andbrine, dried (MgSO₄), and concentrated in vacuo to afford3-(tert-butoxycarbonylamino)-2-(4-((tnisopropylsilyloxy)methyl)phenyl)propanoicacid (E203) as white solid.

Examples 204-206

Compounds E204-E206 were prepared according to the scheme in FIG. 12,which is a modified procedure by Cheung, S. T. et al. Can. J. Chem.1977, 55, 906-910.

3-(tert-butoxycarbonyl(methyl)amino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoicacid (E204) was prepared from E203 according to the below:

To3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoicacid (E203) in THF under N₂ and cooled to 0° C. was added CH₃I followedby NaH and the solution was warmed and allowed to stir for 18 h. Themixture was taken up in EtOAc and extracted with NH₄Cl_((sat)), dried(MgSO₄), filtered, and evaporated. Column chromatography (SiO₂, 0-10%MeOH/CH₂Cl₂ gradient) gave pure3-(tert-butoxycarbonyl(methyl)amino)-2-(4-((tnisopropylsilyloxy)methyl)phenyl)propanoicacid (E204).

Tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-((triisopropylsilyloxy)methyl)phenyl)propyl(methyl)carbamate(E205) was prepared from E204 according to the below:

To3-(tert-butoxycarbonyl(methyl)amino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoicacid (E204) in pyridine was added was added EDC, DMAP, and6-aminoisoquinoline, and the solution was stirred overnight at roomtemperature. The mixture was poured into NaHCO_(3(sat)) and extractedwith EtOAc. The organics were dried (MgSO₄), filtered, and evaporated.Column chromatography (SiO₂, 0-6% MeOH/CH₂Cl₂ gradient) gave puretert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-((triisopropylsilyloxy)methyl)phenyl)propyl(methyl)carbamate(E205).

Tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropyl(methyl)carbamate(E205-1) was prepared from E205 according to the below:

To tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-((thisopropylsilyloxy)methyl)phenyl)Propyl(methyl)carbamate(E205) in THF under N₂ at 0° C. was added TBAF, and the solution wasstirred for 30 min at 0° C. The reaction was warmed to room temperatureand stirred another 4.5 h. The compound was poured into EtOAc and washedwith NH₄Cl_((sat)), dried (MgSO₄), filtered, and evaporated. Columnchromatography (SiO₂, 0-20% MeOH/CH₂Cl₂ gradient) gave pure tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropyl(methyl)carbamate(E205-1)

4-(3-(tert-butoxycarbonyl(methyl)amino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E205-2) was prepared from E205-1 according to thebelow:

To tert-butyl2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropyl(methyl)carbamate(E205-1) in pyridine was added was added EDC, DMAP, and2,4-dimethylbenzoic acid, and the solution was stirred overnight at roomtemperature. The mixture was poured into NaHCO_(3(sat)) and extractedwith EtOAc. The organics were dried (MgSO₄), filtered, and evaporated.Column chromatography (SiO₂, 0-5% MeOH/CH₂Cl₂ gradient) gave pure4-(3-(tert-butoxycarbonyl(methyl)amino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E205-2).

4-(1-(isoquinolin-6-ylamino)-3-(methylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E206) was prepared from E205-2 according to thebelow:

To4-(3-(tert-butoxycarbonyl(methyl)amino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E205-2) in CH₂Cl₂ was added HCl (4 N in dioxane)and the solution was stirred for 8-10 h. The solvents were evaporated togive pure4-(1-(isoquinolin-6-ylamino)-3-(methylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E206).

Examples 207-211

Using commercially available compounds and largely the procedures setforth in Examples 204-206 and substituting the appropriate startingmaterials, the compounds E206-E211 have been made, shown in Table 6.

TABLE 6 Compounds E206-E211.

E207

E208

E209

E210

E211

Example 212

3-(tert-butoxycarbonylamino)-2-(3-((triisopropylsilyloxy)methyl)phenyl)propanoicacid (E212) was prepared.

Using commercially available compounds and largely the procedures setforth in Examples 198-203 and substituting the appropriate startingmaterials3-(tert-butoxycarbonylamino)-2-(3-((triisopropylsilyloxy)methyl)phenyl)propanoicacid (E212) was made.

Examples 213-216

Using commercially available compounds and largely the procedures setforth in Examples 204-206 and substituting the appropriate startingmaterials, the compounds E213-E216 have been made, shown in Table 7.

TABLE 7 Compounds E213-E216.

E213

E214

E215

E216

Examples 217-225

Using commercially available compounds and largely the procedures setforth in Examples 198-203 and Examples 204-206 and substituting theappropriate starting materials, the compounds E217-E225 could be made,shown in Table 8.

TABLE 8 Compounds E217-E225

E217

E218

E219

E220

E221

E222

E223

E224

E225

Example 226

3-(isopropylamino)-N-(isoquinolin-6-yl)-2-phenylpropanamidedihydrochloride (E226) was prepared as shown below:

To 3-amino-N-(isoquinolin-6-yl)-2-phenylpropanamide in MeOH/AcOH wasadded acetone and NaCNBH₃. Then after 15 min the mixture was poured intoNaHCO_(3(sat)) and extracted with CH₂Cl₂. The organics were dried(Na₂SO₄), filtered, and evaporated. Column chromatography (SiO₂, 5% 2 NNH₃-MeOH/CH₂Cl₂) gave pure3-(isopropylamino)-N-(isoquinolin-6-yl)-2-phenylpropanamide. Thecompound was taken up in CH₂Cl₂ and HCl (1 M in Et₂O) was added. Thesolution was evaporated to give3-(isopropylamino)-N-(isoquinolin-6-yl)-2-phenylpropanamidedihydrochloride (E226).

Examples 227-230

Using commercially available compounds and largely the procedures setforth in Example 226 and substituting the appropriate startingmaterials, the compounds E227-E230 could be made, shown in Table 9.

TABLE 9 Compounds E227-E230.

E227

E228

E229

E230

Examples 231-241

Compounds E231-E241 were prepared according to the scheme in FIG. 13.

Methyl 2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)acetate(E232) was prepared from E231 according to the below:

To 2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)acetic acid(E231) in MeOH at 0° C. was added TMS-CH₂N₂ until the solution persistedin a yellow color and TLC indicated completion of the reaction. Thesolution stirred for 30 min and then was quenched with a few drops ofAcOH. The solvents were evaporated and column chromatography (SiO₂,0-15% EtOAc/Hexanes) gave pure methyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)acetate (E232).

Methyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(1,3-dioxoisoindolin-2-yl)propanoate(E233) was prepared from E232 according to the below:

To a solution of LiHMDS in THF cooled to −78° C. was added a cooledsolution (approx −78° C.) of methyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)acetate (E232) inTHF via syringe. The solution was stirred at −78° C. for 30 min.Bromo-methylphthalimide was added directly to the anion, and thesolution was immediately removed from the −78° C. bath and placed in anice bath and stirred for 2 h. The reaction was then poured intoNH₄Cl_((sat)) and extracted with EtOAc. The organics were dried(Na₂SO₄), filtered, and evaporated. Column chromatography (SiO₂, 15-20%EtOAc/Hexanes) gave pure methyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(1,3-dioxoisoindolin-2-yl)propanoate(E233).

2-(2-(5-(tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-2-carboxyethylcarbamoyl)benzoicacid (E234) was prepared from E233 according to the below:

To methyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(1,3-dioxoisoindolin-2-yl)propanoate(E233) in THF/H₂O was added LiOH*H₂O, and the solution was stirred for1.5 h or until complete conversion to product was visible by LC-MS. Thesolution was then poured into EtOAc/NH₄Cl(sat)/1 N HCl (3:1) and theaqueous layer was further extracted with EtOAc. The organics were dried(Na₂SO₄), filtered, evaporated, and dried to give crude2-(2-(5-(tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-2-carboxyethylcarbamoyl)benzoicacid (E234).

2-(2-(5-(tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)propanamide(E235) was prepared from E234 according to the below:

To2-(2-(5-(tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-2-carboxyethylcarbamoyl)benzoicacid (E234) in pyridine was added EDC, DMAP, and 6-aminoisoquinoline,and the solution was flushed with N₂, capped, and stirred overnight. Themixture was poured into EtOAc/NaHCO_(3(sat)) and the aqueous layer wasfurther extracted with EtOAc. The organics were dried (Na₂SO₄),filtered, and evaporated. Column chromatography (SiO₂, 4% MeOH/CH₂Cl₂)gave pure2-(2-(5-(tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)propanamide(E235).

3-amino-2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-N-(isoquinolin-6-yl)propanamide(E236) was prepared from E235 according to the below:

To2-(2-(5-(tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)propanamide(E235) in EtOH was added NH₂—NH₂ and the solution was stirred for 7 h atroom temperature then heated to 50° C. for 1 h. The solution was cooled,the solids were filtered, and the solvents were evaporated. Columnchromatography (SiO₂, 5-8%2 N NH₃-MeOH/CH₂Cl₂) gave pure3-amino-2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-N-(isoquinolin-6-yl)propanamide (E236).

Tert-butyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E237) was prepared from E236 according to the below:

To 3-amino-2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-N-(isoquinolin-6-yl)propanamide (E236) in CH₂Cl₂at 0° C. was added a solution of Boc₂O in CH₂Cl₂ (also cooled to 0° C.before addition). The solution was stirred at 0° C. for 2 h and thenpoured into CH₂Cl₂ and NaHCO_(3(sat)). The solution was furtherextracted with CH₂Cl₂ and the combined organics were dried (Na₂SO₄),filtered, and evaporated. Column chromatography (SiO₂, 3% MeOH/CH₂Cl₂)gave pure tert-butyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E237).

Tert-butyl2-(5-(hydroxymethyl)thiophen-2-yl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E238) was prepared from E237 according to the below:

To tert-butyl2-(5-((tert-butyldimethylsilyloxy)methyl)thiophen-2-yl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E237) in THF at 0° C. was added TBAF and the solution was stirred for0° C. for 30 min then warmed to room temperature for 2 h. The compoundwas poured into EtOAc and washed with NH₄Cl_((sat)), dried (Na₂SO₄),filtered, and evaporated. Column chromatography (SiO₂, 6% MeOH/CH₂Cl₂)gave pure tert-butyl2-(5-(hydroxymethyl)thiophen-2-yl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E238).

3-amino-2-(5-(hydroxymethyl)thiophen-2-yl)-N-(isoquinolin-6-yl)propanamidedihydrochloride (E239) was prepared from E238 according to the below:

To a solution of tert-butyl2-(5-(hydroxymethyl)thiophen-2-yl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E238) in CH₂Cl₂ was added 4 N HCl-dioxane and the solution was stirredfor 4 h. The solvents were evaporated to give3-amino-2-(5-(hydroxymethyl)thiophen-2-yl)-N-(isoquinolin-6-yl)propanamidedihydrochloride (E239).

(5-(3-tert-butoxylcarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)methyl2,4 dimethylbenzoate (E240) was prepared from E239 according to thebelow:

To tert-butyl2-(5-(hydroxymethyl)thiophen-2-yl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E238) in pyridine was added EDC, DMAP, and 2,4-dimethyl benzoic acid,and the solution was flushed with N₂, capped, and stirred overnight. Themixture was poured into EtOAc/NaHCO_(3(sat)) and the aqueous layer wasfurther extracted with EtOAc. The organics were dried (Na₂SO₄),filtered, and evaporated. Column chromatography (SiO₂, 4% MeOH/CH₂Cl₂)gave pure(5-(3-tert-butoxylcarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)methyl2,4 dimethylbenzoate (E240).

(5-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)thiophen-2-yl)methyl2,4-dimethylbenzoate dihydrochloride (E241) was prepared from E240according to the below:

To(5-(3-tert-butoxylcarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)methyl2,4 dimethylbenzoate (E240) in CH₂Cl₂ was added HCl (4 N in dioxane) andthe solution was stirred overnight. The solvents were evaporated to givepure(5-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)thiophen-2-yl)methyl2,4-dimethylbenzoate dihydrochloride (E241).

Examples 242-248

Using commercially available compounds and largely the procedures setforth in Examples 231-241 and substituting the appropriate startingmaterials, E242-E248 could be synthesized, shown in Table 10.

TABLE 10 Compounds E242-E248.

Example R¹ R² 242 —CH₂Ph H 243 -3,5-diMePh H 244

Me 245

H 246 —(CH₂)₂CH₃ Me 247 i-Pr H 248 —Ph Me

Examples 249-253

Methyl2-(4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetate(E250) was prepared from E249 according to the scheme in FIG. 14. Totert-butyl2-(4-hydroxyphenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E249) in DMF cooled to −35° C. was added NaH, and the solution wasstirred at −35° C. for 30 min. Then, methyl bromoacetate was added andthe solution was warmed and stirred at 0° C. for 1 h. The solution waspoured into NaHCO_(3(sat))/EtOAc and further extracted with EtOAc. Thecombined organics were dried (Na₂SO₄), filtered, and evaporated. Columnchromatography (SiO₂, 3-4% MeOH/CH₂Cl₂) gave pure methyl2-(4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetate(E250).

2-(4-(3-tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)aceticacid (E251) was prepared from E250 according to the below:

To methyl2-(4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetate(E250) in THF/H₂O/MeOH at 0° C. was added LiOH*H₂O, and the solution wasstirred for 2 h at 0° C. The mixture was then quenched with HCl (1 N,Et₂O) and evaporated. Column chromatography (SiO₂, 20% MeOH/CH₂Cl₂) gavepure2-(4-(3-tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)aceticacid (E251).

2,4-dimethylphenyl2-(4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetate(E252) was prepared from E251 according to the below:

To2-(4-(3-tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)aceticacid (E251) in pyridine was added EDC, DMAP, and 2,4-dimethylphenol, andthe solution was stirred for 5 h. The mixture was then poured intoEtOAc/NaHCO_(3(sat)) and extracted with EtOAc. The combined organicswere dried (Na₂SO₄), filtered, and evaporated. Column chromatography(SiO₂, 2-3% MeOH/CH₂Cl₂) gave 2,4-dimethylphenyl2-(4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetate(E252).

2,4-dimethylphenyl2-(4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetatedihydrochloride (E253) was prepared from E252 according to the below:

To 2,4-dimethylphenyl2-(4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetate(E252) in CH₂Cl₂ was added HCl (4 N, dioxane) and the solution wasstirred overnight. The solvents were evaporated to give2,4-dimethylphenyl2-(4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenoxy)acetatedihydrochloride (E253).

Examples 254-273

Using commercially available compounds and largely the procedures setforth in Examples 249-253 and substituting the appropriate startingmaterials E254-E261 (shown in Table 11) were made and E262-E273 (shownin Table 12) could be synthesized.

TABLE 11 Compounds E254-E261.

Example X R 254 O Me 255 O H 256 O -2,4-diMePh 257 O -i-Pr 258 O —CH₂Ph259 O -3,5-diMePh 260 NH Ph 261 NH —(CH₂)₃CH₃

TABLE 12 Compounds E262-E273.

Example X R¹ R² 262 O Ph H 263 O 4-MeOPh Me 264 O 2,4-di-F—Ph Me 265 O—CH₂Ph H 266 O —CH₂CH═CH₂ H 267 O

Me 268 NH 2,4-diMePh Me 269 NH 3,5-diMePh Me 270 NH 2-F—Ph H 271 NH—CH₂-4-MeOPh Me 272 NH -2-MeOPh H 273 NH -3-pyridyl H

Example 274

Using commercially available compounds and largely the procedures setforth in Examples 249-253 and substituting the appropriate startingmaterials E274 was made.

Examples 275-278

Compounds E275-E278 were prepared according to the scheme presented inFIG. 15. Tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-(2-oxo-2-phenylethoxy)phenyl)propylcarbamate (E275) was prepared from E249 according to the below:

To tert-butyl2-(4-hydroxyphenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E249) in DMF cooled to −35° C. was added NaH and the solution wasstirred at −35° C. for 30 min. Then, 2-bromoacetophenone was added andthe solution was warmed and stirred at 0° C. for 2 h. The solution waspoured into NaHCO_(3(sat))/EtOAc and further extracted with EtOAc. Thecombined organics were dried (Na₂SO₄), filtered, and evaporated. Columnchromatography (SiO₂, 3% MeOH/CH₂Cl₂) gave tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-(2-oxo-2-phenylethoxy)phenyl)propylcarbamate (E275).

3-amino-N-(isoquinolin-6-yl)-2-(4-(2-oxo-2-phenylethoxy)phenyl)propanamidedihydrochloride (E277) was prepared from E275 according to the below:

To tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-(2-oxo-2-phenylethoxy)phenyl)propylcarbamate (E275) in CH₂Cl₂ was added HCl (4 N, dioxane) and thesolution was stirred overnight. The solvents were evaporated to givepure3-amino-N-(isoquinolin-6-yl)-2-(4-(2-oxo-2-phenylethoxy)phenyl)propanamidedihydrochloride (E277).

Tert-butyl2-(4-(2-hydroxy-2-phenylethoxy)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E276) was prepared from E275 according to the below:

To tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(4-(2-oxo-2-phenylethoxy)phenyl)propylcarbamate (E275) in EtOH was added NaBH₄ and the solution wasstirred for 20 min at room temperature. The mixture was then poured intoNaHCO_(3(sat)) and extracted with CH₂Cl₂. The combined organics weredried (Na₂SO₄), filtered, and evaporated. Column chromatography (SiO₂,5% MeOH/CH₂Cl₂) gave pure tert-butyl2-(4-(2-hydroxy-2-phenylethoxy)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E276).

3-amino-2-(4-(2-hydroxy-2-phenylethoxy)phenyl)-N-(isoquinolin-6-yl)propanamidedihydrochloride (E278) was prepared from E276 according to the below:

To tert-butyl2-(4-(2-hydroxy-2-phenylethoxy)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E276) in CH₂Cl₂ was added HCl (4 N, dioxane) and the solution wasstirred overnight. The solvents were evaporated to give3-amino-2-(4-(2-hydroxy-2-phenylethoxy)phenyl)-N-(isoquinolin-6-yl)propanamidedihydrochloride (E278).

Examples 279-288

Using commercially available compounds and largely the procedures setforth in Examples 275-278 and substituting the appropriate startingmaterials E279-E282 (shown in Table 13) were made and E283-E288 (shownin Table 14) could be synthesized.

TABLE 13 Compounds E279-E282.

Example X R 279 O Ph 280 OH Ph 281 O -4-MeOPh 282 O -2-MeOPh

TABLE 14 Compounds E283-E288.

Example X R1 R2 283 O -2-F—Ph Me 284 O -2,4 diCl—Ph H 285 O -3-MePh H286 OH -4-MeOPh H 287 OH -2-MeOPh H 288 OH -3-MePh Me

Examples 289-290

Compounds E289 and E290 were prepared according to the scheme presentedin FIG. 16.

Tert-butyl 3-(isoquinolin-6-ylamino)-3-oxo-2-(phenethoxyphenyl)propylcarbamate (E289) was prepared from E249 according to the below:

To tert-butyl2-(4-hydroxyphenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate(E249) in DMF cooled to −35° C. was added NaH and the solution wasstirred at −40° C. for 30 min. Then, 2-bromoethylbenzene was added andthe solution was warmed and stirred at room temperature for 2 h. Thesolution was poured into NaHCO_(3(sat))/EtOAc and further extracted withEtOAc. The combined organics were dried (Na₂SO₄), filtered, andevaporated. Column chromatography (SiO₂, 3-4% MeOH/CH₂Cl₂) gave puretert-butyl 3-(isoquinolin-6-ylamino)-3-oxo-2-(phenethoxyphenyl)propylcarbamate (E289).

3-amino-N-(isoquinolin-6-yl)-2-(4-phenethoxyphenyl)propanamidedihydrochloride (E290) was prepared from E289 according to the below:

To tert-butyl 3-(isoquinolin-6-ylamino)-3-oxo-2-(phenethoxyphenyl)propylcarbamate (E289) in CH₂Cl₂ was added HCl (4 N, dioxane) and thesolution was stirred overnight. The solvents were evaporated to give3-amino-N-(isoquinolin-6-yl)-2-(4-phenethoxyphenyl)propanamidedihydrochloride (E290).

Examples 291-299

Using commercially available compounds and largely the procedures setforth in Examples 289-290 and substituting the appropriate startingmaterials E291-E292 (Table 15) were made and E294-E299 (Table 16) couldbe synthesized.

TABLE 15 Compounds E291-E292.

Example R 291 —(CH₂)₂Ph 292 —CH₂Ph** ** E292 was synthesized fromprevious schemes carried out in which the benzyl was in place of theTIPS protecting group.

Using commercially available compounds and largely the procedures setforth in Examples 289-290 and substituting the appropriate startingmaterials E293 was made.

TABLE 16 Compounds E294-E299.

Example R1 R2 294 —CH₂ -4-F—Ph H 295 —CH₂-2-MePh Me 296 —CH₂-2-CNPh Me297 —(CH₂)₂-4-MePh H 298 —(CH₂)₂₋2-FPh H 299

H

Examples 300-308

Compounds E300-E308 were prepared according to the scheme in FIG. 17.

Benzyl 2-(4-hydroxyphenyl)acetate (E301) was prepared from E300according to the below:

To 2-(4-hydroxyphenyl)acetic acid in DMF cooled to 0° C. was added K₂CO₃and the solution was stirred for 30 min. Then, benzyl bromide was addedand the solution stirred at 0° C. and was allowed to slowly warm to15-20° C. After all the ice was melted the solution was poured intoNH₄Cl_((sat)) and extracted with EtOAc. The combined organics were dried(Na₂SO₄), filtered, and evaporated. Column chromatography (SiO₂, 0-35%EtOAc/Hex) gave pure benzyl 2-(4-hydroxyphenyl)acetate (E301).

Benzyl 2-(4-(triisopropylsiloxy)phenyl)acetate (E302) was prepared fromE301 according to the below:

To benzyl 2-(4-hydroxyphenyl)acetate (E301) in CH₂Cl₂ at 0° C. was added2,6-lutidine and TIPS-OTf and the solution stirred for 2.5 h at 0° C.The mixture was poured into NH₄Cl_((sat)) and extracted with CH₂Cl₂. Thecombined organics were dried (Na₂SO₄), filtered, and evaporated. Columnchromatography (SiO₂, 0-15% EtOAc/Hex) gave pure benzyl2-(4-(triisopropylsiloxy)phenyl)acetate (E302).

Benzyl 3-cyano-2-(triisopropylsilyloxy)phenyl)propanoate (E303) wasprepared from E302 according to the below:

To a solution of LiHMDS in THF at −78° C. was added a solution of benzyl2-(4-(triisopropylsiloxy)phenyl)acetate (E302) in THF also cooled toapprox −78° C., and this mixture was allowed to stir at −78° C. for 30min. Iodoacetonitrile was then added and the mixture was warmed to 0° C.and stirred for 2 h. The mixture was poured into NH₄Cl_((sat)) andextracted with EtOAc. The combined organics were dried (Na₂SO₄),filtered, and evaporated. Column chromatography (SiO₂, 0-25% EtOAc/Hex)gave pure benzyl 3-cyano-2-(triisopropylsilyloxy)phenyl)propanoate(E303).

Benzyl4-(tertbutoxycarbonylamino)-2-(4-(triisopropylsilyloxy)phenyl)butanoate(E304) was prepared from E303 according to the below:

To a solution of benzyl3-cyano-2-(triisopropylsilyloxy)phenyl)propanoate (E303) in MeOH cooledto 0° C. was added CoCl₂*6H₂O and NaBH₄ and the solution was allowed tostir for 20 min. Then, HCl (1.25 N in MeOH) was added and the solutionstirred an additional 20 min at 0° C. The solvents were evaporated andthe mixture was taken up in CH₂Cl₂ and cooled to 0° C. Boc₂O and NEt₃were added and the solution stirred at 0° C. for 1.5 h. The mixture waspoured into NH₄Cl_((sat)) and extracted with CH₂Cl₂. The combinedorganics were dried (Na₂SO₄), filtered, and evaporated. Columnchromatography (SiO₂, 10-20% EtOAc/Hexanes) gave pure benzyl4-(tertbutoxycarbonylamino)-2-(4-(triisopropylsilyloxy)phenyl)butanoate(E304).

Preparation of4-(tertbutoxycarbonylamino)-2-(4-(triisopropylsilyloxy)phenyl)butanoicacid (E305) was prepared from E304 according to the below:

To benzyl4-(tert-butoxycarbonylamino)-2-(4-(triisopropylsilyloxy)phenyl)butanoate(E304) in EtOAc was added Pd/C (10%) and the solution was kept under aH₂ atomosphere for 2 h. The mixture was filtered over Celite and thesolvent was evaporated to give4-(tert-butoxycarbonylamino)-2-(4-(triisopropylsilyloxy)phenyl)butanoicacid (E305).

Tert-butyl4-(isoquinolin-6-ylamino)-4-oxo-3-(4-(triisopropylsilyloxy)phenyl)butylcarbamate(E306) was prepared from E305 according to the below:

To4-(tert-butoxycarbonylamino)-2-(4-(triisopropylsilyloxy)phenyl)butanoicacid (E305) in pyridine was added EDC, DMAP, and 6-AlQ, and the solutionwas stirred at room temperature overnight. The mixture was poured intoNaHCO_(3(sat)) and extracted with EtOAc. The combined organics weredried (Na₂SO₄), filtered, and evaporated. Column chromatography (SiO₂,4% MeOH/CH₂Cl₂) gave pure tert-butyl4-(isoquinolin-6-ylamino)-4-oxo-3-(4-(triisopropylsilyloxy)phenyl)butylcarbamate(E306).

Preparation of tert-butyl3-(4-hydroxyphenyl)-4-(isoquinolin-6-ylamino)-4-oxobutylcarbamate (E307)was prepared from E306 according to the following:

To tert-butyl4-(isoquinolin-6-ylamino)-4-oxo-3-(4-(triisopropylsilyloxy)phenyl)butylcarbamate(E306) in THF at 0° C. was added TBAF and the solution was stirred at 0°C. for 30 min. The solution was poured into NH₄Cl_((sat)) and extractedwith EtOAc. The combined organics were dried (Na₂SO₄), filtered, andevaporated. Column chromatography (SiO₂, 5-8% MeOH/CH₂Cl₂) gave puretert-butyl3-(4-hydroxyphenyl)-4-(isoquinolin-6-ylamino)-4-oxobutylcarbamate(E307).

Preparation of4-amino-2-(4-hydroxyphenyl)-N-(isoquinolin-6-yl)butanamidedihydrochloride (E308) was prepared from E307 according to the below:

To tert-butyl3-(4-hydroxyphenyl)-4-(isoquinolin-6-ylamino)-4-oxobutylcarbamate (E307)in CH₂Cl₂ was added HCl (4 N in dioxane) and 2 drops of H₂O and thesolution was stirred overnight at room temperature. The solvents wereevaporated to give4-amino-2-(4-hydroxyphenyl)-N-(isoquinolin-6-yl)butanamidedihydrochloride (E308).

Examples 309-318

Using commercially available compounds and largely the procedures setforth in this application and substituting the appropriate startingmaterials E309-E318 could be synthesized.

TABLE 17 Compounds E309-E318.

Example R1 R2 309 H H 310 —CO—Ph Me 311 —CO-2,4-diMePh H 312 —COCH₂Ph H313 —CO(CH₂)₃CH₃ H 314 —CH₂COPh Me 315 —CH₂CO-4-MeOPh Me 316—CH₂—CH(OH)—Ph H 317 —CH₂-3-MeOPh H 318 —(CH₂)₂Ph Me

Examples 319-325

Compounds E319-E325 were prepared according to the scheme in FIG. 18.

Preparation of methyl 3-(diphenylmethyleneamino)-2-phenylpropanoate(E320) was prepared from E319 according to the below:

To methyl 3-amino-2-phenylpropanoate hydrochloride in CH₂Cl₂ was addedbenzophenone imine, and the solution was stirred overnight at roomtemperature. The mixture was then washed with H₂O and the organics weredried (Na₂SO₄), filtered, and evaporated. Column chromatography (SiO₂,5-20% EtOAc/Hexanes) gave pure methyl3-(diphenylmethyleneamino)-2-phenylpropanoate (E320).

Methyl 3-(diphenylmethyleneamino)-2-methyl-2-phenylpropanoate (E321) wasprepared from E320 according to the below:

To a solution of LiHMDS in THF cooled to −78° C. was added a solution ofmethyl 3-(diphenylmethyleneamino)-2-phenylpropanoate (E320) in THF alsocooled to approximately −78° C. This solution stirred for 30 min at −78°C., then methyl iodide was added directly and the solution was warmed to0° C. After 3 h the solution was poured into NH₄Cl_((sat)) and extractedwith EtOAc. The combined organics were dried (Na₂SO₄) filtered, andevaporated. Column chromatography (SiO₂, O-15% EtOAc/Hexanes) gave puremethyl 3-(diphenylmethyleneamino)-2-methyl-2-phenylpropanoate (E321).

3-amino-2-methyl-2-phenylpropanoic acid hydrochloride (E322) wasprepared from E321 according to the below:

A mixture of methyl3-(diphenylmethyleneamino)-2-methyl-2-phenylpropanoate (E321) and 6 NHCl was refluxed overnight. The solution was cooled and evaporated togive 3-amino-2-methyl-2-phenylpropanoic acid hydrochloride (E322).

3-(tert-butoxycarbonylamino)-2-methyl-2-phenylpropanoic acid (E323) wasprepared from E322 according to the below:

To a solution of Boc₂O in dioxane cooled to 0° C. was added a solutionof 3-amino-2-methyl-2-phenylpropanoic acid hydrochloride (E322) in 1 NNaOH and this solution stirred 3 h and the solution was then washed withNaHCO_(3(sat))/CH₂Cl₂. The aqueous layer was acidified with HCl (1 N)and extracted with CH₂Cl₂. These combined organics were dried (Na₂SO₄),filtered, and evaporated to give3-(tert-butoxycarbonylamino)-2-methyl-2-phenylpropanoic acid (E323).

Tert-butyl 3-isoquinolin-6-yl)-2-methyl-3-oxo-2-phenylpropylcarbamate(E324) was prepared from E323 according to the below:

To 3-(tert-butoxycarbonylamino)-2-methyl-2-phenylpropanoic acid (E323)in pyridine was added EDC, DMAP, and 6-AlQ, and solution was stirred atroom temperature for 48 h. The mixture was poured into NaHCO_(3(sat))and extracted with EtOAc. The combined organics were dried (Na₂SO₄),filtered, and evaporated. Column chromatography (SiO₂, 3% MeOH/CH₂Cl₂)gave pure tert-butyl3-isoquinolin-6-yl)-2-methyl-3-oxo-2-phenylpropylcarbamate (E324).

3-amino-N-(isoquinolin-6-yl)-2-methyl-2-phenylpropanamidedihydrochloride (E325) was prepared from E324 according to the below:

To tert-butyl 3-isoquinolin-6-yl)-2-methyl-3-oxo-2-phenylpropylcarbamate(E324) in CH₂Cl₂ was added HCl (4 N in dioxane) and the solution wasstirred overnight at room temperature. The solvents were evaporated togive 3-amino-N-(isoquinolin-6-yl)-2-methyl-2-phenylpropanamidedihydrochloride (E325).

Examples 326-334

Using commercially available compounds and largely the procedures setforth in the Examples above and substituting the appropriate startingmaterials, E326-E334 could be synthesized, shown in Table 18.

TABLE 18 Compounds E326-E334.

Example X n R¹ R² 326 —OH 1 Me Me 327 —CH₂OH 1 Me H 328 —OCOPh 2 Me H329 —OCO-2,4-diMePh 1 —CH₂Ph H 330 —OCOCH₂Ph 1 —CH₂Ph H 331—CH₂OCO-3,5-diMePh 1 Me H 332 —CH₂OCO-2,4-diMePh 1 —CH₂-4-MeOPh Me 333—CH₂OCO—(CH₂)₂CH₃ 1 —CH₂-2-MeOPh H 334 —CH₂OCO-2,4-diMePh 2 Me H

Examples 335-338

2-fluoro-4-nitrobenzamide (E335) was prepared according to the below:

To 2-fluoro-4-nitrobenzoic acid suspended in CH₂Cl₂ under Ar was addedDMF then oxalyl chloride. The reaction was stirred at room temperature1.5 h then the solvent was evaporated. The residue was dissolved in THFand ammonia gas was bubbled through the reaction for 15 min. The solventwas evaporated and the residue partitioned between EtOAc and water. Theaqueous layer was extracted with EtOAc. The extracts were dried (MgSO₄),filtered, and evaporated. Column chromatography (SiO₂, 0-100% EtOAc/Hex)gave pure 2-fluoro-4-nitrobenzamide (E335).

4-amino-2-fluorobenzamide (E336) was prepared from E335 according to thebelow:

2-fluoro-4-nitrobenzamide (E335) was dissolved in EtOH under Ar and 10%Pd/C added. The reaction was pump-purged with H₂ and left stirring atroom temperature overnight. The catalyst was removed by filtration andthe reaction concentrated to give pure 4-amino-2-fluorobenzamide (E336).

Tert-butyl3-(4-carbamoyl-3-fluorophenylamino)-3-oxo-2-(4-((triisopropylsilyloxy)methyl)phenyl)propylcarbamate(E337) was prepared from E336 according to the below:

To3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoicacid in pyridine was added EDC, DMAP, and 4-amino-2-fluorobenzamide(E336), and the solution was stirred overnight at room temperature. Themixture was poured into NaHCO_(3(sat)) and extracted with EtOAc. Theextracts were dried (MgSO₄), filtered, and evaporated. Columnchromatography (SiO₂, 0-6% MeOH/CH₂Cl₂ gradient) gave pure tert-butyl3-(4-carbamoyl-3-fluorophenylamino)-3-oxo-2-(4-((triisopropylsilyloxy)methyl)phenyl)propylcarbamate(E337).

Tert-butyl3-(4-carbamoyl-3-fluorophenylamino)-2-(4-(hydroxymethyl)phenyl)-3-oxopropylcarbamate(E337-1) was prepared from E337 according to the below:

To tert-butyl3-(4-carbamoyl-3-fluorophenylamino)-3-oxo-2-(4-((thisopropylsilyloxy)methyl)phenyl)propylcarbamate(E337) in THF under N₂ at 0° C. was added TBAF, and the solution wasstirred for 30 min at 0° C. The reaction was warmed to room temperatureand stirred another 3.5 h. The compound was poured into EtOAc and washedwith NH₄Cl_((sat)), dried (MgSO₄), filtered, and evaporated. Columnchromatography (SiO₂, 0-20% MeOH/CH₂Cl₂ gradient) gave pure tert-butyl3-(4-carbamoyl-3-fluorophenylamino)-2-(4-(hydroxymethyl)phenyl)-3-oxopropylcarbamate(E337-1)

4-(3-(tert-butoxycarbonylamino)-1-(4-carbamoyl-3-fluorophenylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E337-2) was prepared from E337-1 according to thebelow:

To tert-butyl3-(4-carbamoyl-3-fluorophenylamino)-2-(4-(hydroxymethyl)phenyl)-3-oxopropylcarbamate(E337-1) in pyridine was added was added EDC, DMAP, and2,4-dimethylbenzoic acid, and the solution was stirred overnight at roomtemperature. The mixture was poured into NaHCO_(3(sat)) and extractedwith EtOAc. The organics were dried (MgSO₄), filtered, and evaporated.Column chromatography (SiO₂, O-5% MeOH/CH₂Cl₂ gradient) gave pure4-(3-(tert-butoxycarbonylamino)-1-(4-carbamoyl-3-fluorophenylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E337-2).

4-(3-amino-1-(4-carbamoyl-3-fluorophenylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E338) was prepared from E337-2 according to thebelow:

To4-(3-(tert-butoxycarbonylamino)-1-(4-carbamoyl-3-fluorophenylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E337-2) in CH₂Cl₂ was added HCl (4 N in dioxane)and the solution was stirred overnight. The solvents were evaporated togive pure4-(3-amino-1-(4-carbamoyl-3-fluorophenylamino)-1-oxopropan-2-yl)benzyl2,4-di methyl benzoate (E338).

Examples 339-370

Using commercially available compounds and largely the procedures setforth in Examples 335-338 and substituting the appropriate startingmaterials, the compounds E339-E354 (Table 19) and E355-E370 (Table 20)could be made.

TABLE 19 Compounds E339-E354.

Example R1 R2 R3 R4 R5 339 H Bu H H F 340 Me Bu H H F 341 H Ph H H H 342Me Ph H H H 343 H 3,5-diMePh F H H 344 H 2,4-diMePh H F H 345 H Bn H H F346 H cyclohexyl Me H H 347 Me cyclopentyl H Me H 348 Me 3-MePh H H Me349 H 4-MePh H H H 350 H 3-thienyl H H H 351 Me 2,4-diFPh H H H 352 H3,5-diClPh H H H 353 Me 2-thienyl H H H 354 H 4-MeOPh H H H

TABLE 20 Compounds E355-E370.

Example R1 R2 R3 R4 R5 355 H Bu H H F 356 Me Bu H H F 357 H Ph H H H 358Me Ph H H H 359 H 3,5-diMePh F H H 360 H 2,4-diMePh H F H 361 H Bn H H F362 H cyclohexyl Me H H 363 Me cyclopentyl H Me H 364 Me 3-MePh H H Me365 H 4-MePh H H H 366 H 3-thienyl H H H 367 Me 2,4-diFPh H H H 368 H3,5-diClPh H H H 369 Me 2-thienyl H H H 370 H 4-MeOPh H H H

Examples 371-377

Compounds E371-E377 were prepared according to the scheme in FIG. 19.

For the preparation of methyl3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E372), to a 0° C. solution of methyl3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoicacid (E371) in MeOH was added a 2.0 M solution oftrimethylsilyldiazomethane in hexanes. The solution was stirred for 20min at room temperature and then quenched by the addition of a few dropsof AcOH. The solution was concentrated and the residue, methyl3-(tert-butoxycarbonylamino)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanoate(E372), was used without purification.

For the preparation of methyl3-(tert-butoxycarbonylamino)-2-(4-(hydroxymethyl)phenyl)propanoate(E373), to a 0° C. solution of methyl3-(tert-butoxycarbonylamino)-2-(4-((tnisopropylsilyloxy)methyl)phenyl)propanoate(E372) in THF was added a 1 M solution of tetrabutylammonium fluoride inTHF, and the reaction was stirred overnight at room temperature. Thereaction was quenched with saturated aqueous NH₄Cl, and extracted withEtOAc (3×). The combined organics were washed with brine, dried overNa₂SO₄, and concentrated. The residue was purified by silica gel columnchromatography (eluting with 0% to 50% EtOAc/hexanes) to yield methyl3-(tert-butoxycarbonylamino)-2-(4-(hydroxymethyl)phenyl)propanoate(E373).

For the preparation of4-(3-(tert-butoxycarbonylamino)-1-methoxy-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E374, R=2,4-Me₂Ph), to a solution of methyl3-(tert-butoxycarbonylamino)-2-(4-(hydroxymethyl)phenyl)propanoate(E373) in pyridine was added1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI),4-(dimethylamino)pyridine (DMAP), and 2,4-dimethylbenzoic acid. Thereaction was stirred overnight at room temperature. After addition ofEtOAc and saturated aqueous NaHCO₃, the mixture was extracted with EtOAc(3×). The combined organics were washed with brine, dried over Na₂SO₄,and concentrated. The residue was purified by silica gel columnchromatography (eluting with 20% to 80% EtOAc/hexanes) to yield4-(3-(tert-butoxycarbonylamino)-1-methoxy-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E374, R=2,4-Me₂Ph).

For the preparation of3-(tert-butoxycarbonylamino)-2-(4-((2,4-dimethylbenzoyloxy)methyl)phenyl)propanoicacid (E375, R=2,4-Me₂Ph), to a solution of4-(3-(tert-butoxycarbonylamino)-1-methoxy-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E374, R=2,4-Me₂Ph) in 2:1 THF/H₂O was addedLiOH.H₂O and the solution was stirred at room temperature for 3 h. Afteraddition of 1 N HCl (until the pH was acidic), the mixture was extractedwith EtOAc (3×). The combined organics were washed with brine, driedover Na₂SO₄, filtered, and concentrated to yield3-(tert-butoxycarbonylamino)-2-(4-((2,4-dimethylbenzoyloxy)methyl)phenyl)propanoicacid (E375, R=2,4-Me₂Ph).

For the preparation of4-(3-(tert-butoxycarbonylamino)-1-(1-methoxyisoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E376, R=2,4-Me₂Ph, X=1-OMe), to a solution of3-(tert-butoxycarbonylamino)-2-(4-((2,4-dimethylbenzoyloxy)methyl)phenyl)propanoicacid (E375, R=2,4-Me₂Ph) in pyridine was added EDCI, DMAP, and6-amino-1-methoxyisoquinoline. The solution was stirred overnight atroom temperature. The mixture was diluted with EtOAc and saturated aq.NaHCO₃ solution. The mixture was extracted with EtOAc (3×). The combinedorganics were washed with brine, dried over Na₂SO₄, and concentrated.The residue was purified by silica gel column chromatography (elutingwith 0% to 80% EtOAc/hexanes) to yield4-(3-(tert-butoxycarbonylamino)-1-(1-methoxyisoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E376, R=2,4-Me₂Ph, X=1-OMe).

For the preparation of4-(3-amino-1-(1-methoxyisoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-di methyl benzoate (E377, R=2,4-Me₂Ph, X=1-OMe), to a solution of4-(3-(tert-butoxycarbonylamino)-1-(1-methoxyisoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E376, R=2,4-Me₂Ph, X=3-Me) in CH₂Cl₂ was added 4NHCl in dioxane and the solution was stirred overnight at roomtemperature. The solution was concentrated. The residue was diluted withdichloromethane and concentrated again to yield4-(3-amino-1-(1-methoxyisoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl2,4-dimethylbenzoate (E377, R=2,4-Me₂Ph, X=2-OMe) as the hydrochloridesalt.

Examples 378-380

Using largely the procedures shown above, the following compoundsE378-E380 were synthesized, shown in Table 21.

TABLE 21 Compounds E378-E380.

Example R 378

379

380

Examples 381-397

Using largely the procedures shown above, the following compoundsE381-E397 could be synthesized, shown in Table 22.

TABLE 22 Compounds E381-E397.

Example R 381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

Examples 398-404

Compounds E399-E404 were prepared according to the scheme in FIG. 20.

Methyl 2-phenyl-3-(triisopropylsilyloxy)propanoate (E399) was preparedfrom E398 according to the below:

To methyl 3-hydroxy-2-phenylpropanolate in CH₂Cl₂ was at 0° C. was added2,6-lutidine and TIPS-OTf, and this solution was stirred for 2 h at roomtemperature. The mixture was poured into NH₄Cl_((sat)) and extractedwith CH₂Cl₂. The organics were dried (Na₂SO₄), filtered, and evaporated.Column chromatography 0-10% EtOAc/Hex gave pure methyl2-phenyl-3-(triisopropylsilyloxy)propanoate (E399).

2-phenyl-3-(triisopropylsilyloxy)propanoic acid (E400) was prepared fromE399 according to the below:

To methyl 2-phenyl-3-(triisopropylsilyloxy)propanoate (E399) inTHF/H₂O/MeOH was added LiOH*H₂O and the solution was stir at roomtemperature overnight. The solution was poured into NH₄Cl_((sat))/HCl (1N) (3:1) and extracted with EtOAc. The combined organics were dried(Na₂SO₄), filtered, and evaporated. Column chromatography (0%-4%MeOH/CH₂Cl₂) gave pure 2-phenyl-3-(triisopropylsilyloxy)propanoic acid(E400).

N-(isoquinolin-6-yl)-2-phenyl-3-(triisopropylsilyloxy)propanamide (E401)was prepared from E400 according to the below:

To 2-phenyl-3-(triisopropylsilyloxy)propanoic acid (E400) in pyridinewas added EDC, DMAP, and 6-aminoisoquinoline, and the solution wasflushed with N₂, capped, and stirred overnight. The mixture was pouredinto NaHCO_(3(sat)) and extracted with EtOAC. The combined organics weredried (Na₂SO₄), filtered, and evaporated. Column chromatography (3-4%MeOH/CH₂Cl₂) gave pureN-(isoquinolin-6-yl)-2-phenyl-3-(triisopropylsilyloxy)propanamide(E401).

3-hydroxy-N-(isoquinolin-6-yl)-2-phenylpropanamide (E402) was preparedfrom E401 according to the below:

To N-(isoquinolin-6-yl)-2-phenyl-3-(triisopropylsilyloxy)propanamide(E401) in THF cooled to 0° C. was added TBAF and this solution wasstirred for 3 h at 0° C. The mixture was poured into EtOAc/NH₄Cl_((sat))and washed with NH₄Cl_((sat)). The organics were dried (Na₂SO₄),filtered, and evaporated. Column chromatography (0-10% MeOH/CH₂Cl₂) gavepure 3-hydroxy-N-(isoquinolin-6-yl)-2-phenylpropanamide (E402).

3-(isoquinolin-6-ylamino)-3-oxo-2-phenylpropyl methanesulfonate (E403)was prepared from E402 according to the below:

To 3-hydroxy-N-(isoquinolin-6-yl)-2-phenylpropanamide (E402) in pyridineat 0° C. was added MsCl, and this solution was stirred at 0° C. for 2.5h. The mixture was poured into NaHCO_(3(sat)) and extracted with EtOAc.The combined organics were dried (Na₂SO₄), filtered, and evaporated togive 3-(isoquinolin-6-ylamino)-3-oxo-2-phenylpropyl methanesulfonate(E403).

N-(isoquinolin-6-yl)-3-(4-methylpiperazin-1-yl)-2-phenylpropanamide(E404) was prepared from E403 according to the below:

To 3-(isoquinolin-6-ylamino)-3-oxo-2-phenylpropyl methanesulfonate(E403) in methanol was added 1-methypiperazine, and the solution wasstirred overnight at 50° C. The solvents were evaporated and columnchromatography 10-20% 2 N NH₃-MeOH/CH₂Cl₂ gaveN-(isoquinolin-6-yl)-3-(4-methylpiperazin-1-yl)-2-phenylpropanamide(E404).

Examples 405-428

Using commercially available compounds and largely the procedures setforth in the previous examples and substituting the appropriate startingmaterials, the compounds E405-E410 (Table 23) and E411-E428 (Table 24and Table 25) could be synthesized.

TABLE 23 Compounds E405-E410.

  4-(1-(isoquinolin-6-ylamino)-1-oxo-3-(4-phenylpiperazin-1-yl)propan-2-yl)phenyl 2- phenylacetate 405

  4-(3-(4-acetylpiperazin-1-yl)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)phenyl benzoate 406

  4-(3-(4-(cyclopropylmethyl)piperazin-1-yl)-1-(isoquinolin-6-ylamino)-1-oxopropan-2- yl)phenyl 3,5-dimethylbenzoate407

  3-(1,4-diazepan-1-yl)-N-(isoquinolin-6-yl)-2-(4-(2-oxo-2-phenylethoxy)phenyl)propanamide 408

  4-(3-(4-benzyl-1,4-diazepan-1-yl)-1-(isoquinolin-6-ylamino)-1-oxopropan-2- yl)phenyl 2-phenylacetate 409

  4-(1-(isoquinolin-6-ylamino)-1-oxo-3-(piperidin-1-yl)propan-2-yl)phenyl 2-phenylpropanoate 410

TABLE 24 Compounds E411-E419.

Example R¹ R² R³ n 411 Me Me CO-2,4diMePh 1 412 Me Me CO—CH2Ph 1 413 MeCH₂-4-HOPh CO—(CH₂)₂CH₃ 1 414 Me CH₂₋2-HOPh CH₂—COPh 1 415 Me CH₂-4-FPhCH₂CO-4-MeOPh 1 416 Et CH₂—Ph CH₂C(OH)-2-MeOPh 2 417 Et Me CH₂CH₂Ph 2418 Me CH₂-3-pyridyl COBn 2 419 Me CH₂-4-pyridyl COPh 2

TABLE 25 Compounds E420-E428.

Example R¹ R² R³ n 420 Me Me CO-2,4diMePh 1 421 Me Me

1 422 Me CH₂-4-MeOPh CO—(CH2)2CH3 2 423 Me CH₂-2-HOPh CO-4-MePh 1 424 MeCH₂-3-FPh COPh 1 425 Et CH2—Ph CO-3,5-diMePh 2 426 Et Me CO—Bn 1 427 Me

CO(CH₂)₂CH₃ 2 428 Me CH₂-4-pyridyl CO(CH₂)₂Ph 1

Examples 429-433

Compounds E429-E433 were prepared according to the scheme in FIG. 21,which is a modified procedure of Calmes et al., Eur. J. Org. Chem. 2000,2459-2466.

Methyl 3-(1,3-dioxoisoindolin-2-yl)-2-(thiophen-3-yl)propanoate (E429)was prepared according to the below:

To pure methyl 2-(thiophen-3-yl)acetate in THF cooled to −78° C. wasadded LiHMDS and the solution stirred at −78° C. for 30 min. ThenN-(bromomethyl)phthalimide was added directly and the solution wasallowed to warm to 0° C. The mixture was poured into NaHCO_(3(sat))extracted with EtOAc, dried (Na₂SO₄), filtered, and evaporated. Columnchromatography (SiO₂, 0-40% EtOAc/Hex) gave pure methyl3-(1,3-dioxoisoindolin-2-yl)-2-(thiophen-3-yl)propanoate (E429).

3-amino-2-(thiophen-3-yl)propanoic acid hydrochloride (E430) wasprepared from E429 according to the below:

To methyl 3-(1,3-dioxoisoindolin-2-yl)-2-(thiophen-3-yl)propanoate(E429) was added 6 N HCl and the solution was refluxed for 4 h. Thesolvents were evaporated to give 3-amino-2-(thiophen-3-yl)propanoic acid(E430).

3-(tert-butoxycarbonylamino)-2-(thiophen-3-yl) propanoic acid (E431) wasprepared from E430 according to the below:

To Boc₂O in dioxane at 0° C. was added a cooled solution (0° C.) of3-amino-2-(thiophen-3-yl)propanoic acid hydrochloride (E430) in 1 NNaOH. The solution was stirred at 0° C. for 30 min, then at roomtemperature for 4 h. The mixture was acidified with HCl and extractedwith EtOAc and NH₄Cl_((sat)). The organics were dried (Na₂SO₄),filtered, and evaporated to give pure of3-(tert-butoxycarbonylamino)-2-(thiophen-3-yl)propanoic acid (E431).

Tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(thiophen-3-yl)propylcarbamate (E432)was prepared from E431 according to the below:

To 3-(tert-butoxycarbonylamino)-2-(thiophen-3-yl)propanoic acid (E431)in pyridine was added was added EDC, DMAP, and 6-aminoisoquinoline, andthe solution was stirred overnight at room temperature. The mixture waspoured into NaHCO_(3(sat)) and extracted with EtOAc. The organics weredried (Na₂SO₄), filtered, and evaporated. Column chromatography (SiO₂,3% MeOH/CH₂Cl₂) gave pure tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(thiophen-3-yl) propylcarbamate(E432).

3-amino-N-(isoquinolin-6-yl)-2-(thiophen-3-yl)propanamidedihydrochloride (E433) was prepared from E432 according to the below:

To tert-butyl3-(isoquinolin-6-ylamino)-3-oxo-2-(thiophen-3-yl)propylcarbamate (E432)in CH₂Cl₂ was added HCl (4 N in dioxane) and the solution was stirredfor 8-10 h. The solvents were evaporated to give pure3-amino-N-(isoquinolin-6-yl)-2-(thiophen-3-yl)propanamidedihydrochloride (E433).

Examples 434-456

Using commercially available compounds and largely the procedures setforth in Examples 429-433 and substituting the appropriate startingmaterials, the following compounds E434-E441 (Table 26) and E442-E456(Table 27) were made.

TABLE 26 Compounds E434-E441.

Example X R₄ R₂ R₁ 434 H (±)-3-thienyl Me Me 435 H (±)-3-thienyl H H 436H C₆H₅ H H 437 H C₆H₅ Me Me 438 F C₆H₅ H H 439 F C₆H₅ Me Me 440 H(±)-2-thienyl H H 441 Cl (±)-2-thienyl Me Me

TABLE 27 Compounds E442-E456.

Example X R₄ R₂ R₁ 442 H (R)-C₆H₅ H H 443 H (S)-C₆H₅ H H 444 OHp-fluoro-C₆H₄ Me Me 445 H p-fluoro-C₆H₄ benzyl H 446 H Benzyl Me H 447 Hp-fluoro benzyl Me H 448 OH 3-pyridyl H H 449 H 4-pyridyl Me Me 450 OH3-furyl H H 451 H cyclopropyl Me Me 452 H cyclopentyl Me Me 453 OHcyclohexyl H H 454 H 3-benzo[b]thiophene Me Me 455 H

H H 456 OH 2-oxazole H H

Example 457

Topical pharmaceutical compositions for lowering intraocular pressureare prepared by conventional methods and formulated as follows:

Ingredient Amount (wt %) Active ingredient 0.50 Dextran 70 0.1Hydroxypropyl methylcellulose 0.3 Sodium chloride 0.77 Potassiumchloride 0.12 Disodium EDTA 0.05 Benzalkonium chloride 0.01 HCl and/orNaOH pH 5.5-6.5 Purified water q.s. to 100%

A compound according to this invention is used as the active ingredient.When the composition is topically administered to the eyes once daily,the above composition decreases intraocular pressure in a patientsuffering from glaucoma.

Example 458

Example 457 is repeated using E6 according to this invention. Whenadministered as a drop 2 times per day, the above compositionsubstantially decreases intraocular pressure and serves as aneuroprotective agent.

Example 459

Example 457 is repeated using a gamma amino acid isoquinolyl amideaccording to this invention. When administered as a drop twice per day,the above composition substantially decreases intraocular pressure.

Example 460

Example 457 is repeated using a benzamide according to this invention.When administered as a drop twice per day, the above compositionsubstantially decreases allergic symptoms and relieves dry eye syndrome.

Example 461

Example 457 is repeated using E19 according to this invention. Whenadministered as a drop as needed, the above composition substantiallydecreases hyperemia, redness, and ocular irritation.

Example 462

Example 457 is repeated using E18 according to this invention. Whenadministered as a drop 4 times per day, the above compositionsubstantially decreases intraocular pressure and serves as aneuroprotective agent.

Example 463

Example 457 is repeated using E21 according to this invention. Whenadministered as a drop twice per day, the above compositionsubstantially decreases intraocular pressure.

Example 464

Example 457 is repeated using E115 according to this invention. Whenadministered as a drop twice per day, the above compositionsubstantially decreases ocular pressure, allergic symptoms, and relievesdry eye syndrome.

Reference Example 2 Cell-Based Porcine Trabecular Meshwork (PTM) Assay

The anterior section of porcine eyes are harvested within 4 hpost-mortem. The iris and ciliary body are removed and trabecularmeshwork cells are harvested by blunt dissection. Finely mincedtrabecular meshwork tissue are plated into collagen-coated 6-well platesin Medium-199 containing 20% fetal bovine serum (FBS). After twopassages at confluence, cells are transferred to low-glucose DMEMcontaining 10% FBS. Cells are used between passage 3 and passage 8.

Cells are plated into fibronectin-coated, glass multiwell plates the daybefore compound testing under standard culture conditions. Compounds areadded to cells in the presence of 1% FBS-containing DMEM and 1% DMSO.When compounds are incubated with the cells for the duration determinedto be optimal, the media and compound is removed and cells fixed for 20min in 3% methanol-free paraformaldehyde. Cells are rinsed twice withphosphate buffered saline (PBS) and cells are permeabilized with 0.5%Triton X-100 for two min. Following an additional two washes with PBS,F-actin is stained with Alexa-fluor 488-labelled phalloidin and nucleiare stained with DAPI.

Data is reduced to the mean straight actin-fiber length and normalizedto DMSO-treated control cells (100%) and 50 μM Y-27632 (0%). Y-27632 isa rho-kinase inhibitor known to result in the depolymerization ofF-actin in these cells.

Reference Example 3 Norepinephrine Transporter (NET) MembraneRadioligand Binding Assays

Total cell membranes are prepared from MDCK cells expressing therecombinant human norepinehrine transporter (hNET) grown to confluencein 150 mm tissue culture dishes. Cells are scraped into standard mediumand pelleted at 1600 g. The medium is discarded and the pelletresuspended in 5 mL per plate of ice-cold binding buffer (100 mM NaCl,50 mM Tris, pH 7.4 at room temperature) by trituration, and the cellsare repelleted at 20,000 g. Supernatant is discarded and cells areresuspended in binding buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 μMleupeptin, 10 μM PMSF) and homogenized with a polytron (Brinkman) at25,000 revs/min for 5 s. Centrifugation, resuspension, andhomogenization are repeated and a sample of suspension is used forBradford protein determination (BioRad). Samples of membrane suspensionsare frozen at −80° C. prior to use. Typical yields are about 100 μgmembrane protein per 106 cells. Assays performed in duplicate areinitiated with 0.2 nM [125I]RTI-55. Non-specific binding is determinedby the inclusion of 10 μM desipramine. Incubation is carried out for 3 hat 4° C. Assays are terminated by rapid filtration over GF/B glass-fiberfilters soaked in 0.5% polyethylineimine using an automated cellharvester (Brandel) followed by three rapid 5 mL washes in ice-coldbinding buffer. Bound radioactivity is measured by gamma emissionspectrometry.

Reference Example 4 Serotonin Transporter (SERT) Membrane RadioligandBinding Assays

Total cell membranes are prepared from HEK-293 cells expressing therecombinant human serotonin transporter (hSERT) grown to confluence in150 mm tissue culture dishes. Cells are scraped into standard medium andpelleted at 1600 g. The medium is discarded and the pellet resuspendedin 5 mL per plate of ice-cold binding buffer (100 mM NaCl, 50 mM Tris,pH 7.4 at room temperature) by trituration, and the cells are repelletedat 20,000 g. Supernatant is discarded and cells are resuspended inbinding buffer (50 mM Tris-HCl, pH 7.4, 120 mM NaCl, 5 mM KCl) andhomogenized with a polytron (Brinkman) at 25,000 revs/min for 5 s.Centrifugation, resuspension, and homogenization are repeated, and asample of suspension is used for Bradford protein determination(BioRad). Samples of membrane suspensions are frozen at −80° C. prior touse. Typical yields are about 100 μg membrane protein per 106 cells.Assays performed in duplicate are initiated with 0.4 nM [3H]paroxetine.Non-specific binding is determined by the inclusion of 10 μM imipramine.Incubation is carried out for 60 min at 25° C. Assays are terminated byrapid filtration over GF/B glass-fiber filters soaked in 0.5%polyethylineimine using an automated cell harvester (Brandel) followedby three rapid 5 mL washes in ice-cold binding buffer. Boundradioactivity is measured by beta emission spectrometry.

Reference Example 5 Pharmacological Activity for Glaucoma Assay

Pharmacological activity for glaucoma treatment can be demonstratedusing assays designed to test the ability of the subject compounds todecrease intraocular pressure. Examples of such assays are described inthe following reference, incorporated herein by reference: C. Liljebris,G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, “Derivatives of17-phenyl-18,19,20-trinorprostaglandin F₂ Ispropyl Ester: PotentialAnti-glaucoma Agents”, Journal of Medicinal Chemistry 1995, 38 (2):289-304.

Reference Example 6 Functional Screen for NET Activity Modulators

At the center of the cellular assay used to characterized inhibition ofthe human norepinephrine transporter (hNET) is a fluorophore whichmimics a biogenic amine and is actively transported in to the cell.After incubation with a potential inhibitor, the dye solution is addedin the presence of a fluorescence masking dye. When the fluorescent dyeis transported into the cell and removed from the masking dye, light isemitted at a wavelength of 510 nm when excited with light of 425 nm.Inhibitors of the norepinephrine transporter prevent this time-dependentincrease in fluorescence. (Blakely R D, DeFelice L J, and Galli A. A.Physiol. 2005. 20, 225-231).

HEK-293 cells recombinantly over-expressing the human NorepinephrineTransporter are grown in phenol red-free DMEM medium (Gibco #21063-029)containing 10% fetal bovine serum (Atlanta Biologicals #S11050), 100units/mL penicillin/streptomycin (Gibco #15140-122), and 250 μg/mL G-418(Gibco #10131027) at 37° C. and 5% CO₂.

One day prior to testing, cells are plated into black, clear bottomplates (Costar #3904) at a density of 100,000 per well. On the morningof the assay, culture media is removed and replaced with 100 μL of HBSS(1× Hank's Balanced Salt Solution containing 20 mM HEPES) (10×HBSS Gibco#14065, 1 M HEPES Gibco #15630-80) containing test compound. Cells areexposed to the test compound (or DMSO in control wells) for 30 min. Atthe end of the pre-incubation period, 10 μL of 10× dye solution is addedand thoroughly mixed with the compound solution. After a 30 minincubation period, fluorescence is quantified using an Analyst HTfluorescence plate reader (Molecular Devices, Sunnyvale, Calif.).

While the invention has been described in detail and with reference tospecific embodiments thereof, it will be apparent to one skilled in theart that various changes and modifications can be made without departingfrom the spirit and scope of the invention.

What is claimed is:
 1. A compound according to Formula II:

and salts thereof, wherein R¹, R², and R³ are independently hydrogen, C₁-C₄ alkyl, aryl, C₁-C₄ alkyl aryl, C₁-C₄ alkyl heteroaryl, C₁-C₄ alkyl heterocyclyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄ alkoxy, C₁-C₄ sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, C₁-C₄ carboxyl, or form a ring with each other or with A; wherein A is C₁-C₄ alkyl, or forms a ring structure with R¹, R², or R³; wherein B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C₁-C₂₂ alkyl, C₁-C₂₂ alkyl aryl, C₁-C₂₂ alkyl heteroaryl, C₂-C₂₂ alkenyl, C₂-C₂₂ alkynyl, C₁-C₂₂ carbonyl, C₁-C₂₂ carbonylamino, C₁-C₂₂ alkoxy, C₁-C₂₂ sulfonyl, C₁-C₂₂ sulfonylamino, C₁-C₂₂ thioalkyl, or C₁-C₂₂ carboxyl; wherein X¹, X², and X³ are, independently, hydrogen, hydroxyl, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, amino, aminocarbonyl, nitro, cyano, C₁-C₄ carbonyl, C₁-C₄ carbonylamino, C₁-C₄ alkoxy, C₁-C₄ sulfonyl, C₁-C₄ sulfonylamino, C₁-C₄ thioalkyl, or C₁-C₄ carboxyl; wherein the double circle

indicates an aromatic or heteroaromatic ring; and wherein each Z is independently a bond, C₁-C₄ alkyl, heteroalkyl, or an O atom.
 2. A compound according to claim 1, wherein R¹ is hydrogen or C₁-C₄ alkyl; B is C₁-C₂₂ carbonyl; X₁, X₂, and X₃ are hydrogen; the double circle

indicates an aromatic or heteroaromatic ring; and Z is a bond, C₁-C₄ alkyl, C₁-C₄ heteroalkyl, or an O atom.
 3. A compound according to claim 1, wherein Z is a bond or —CH₂—.
 4. A compound according to claim 1, wherein X¹, X² and X³ are each hydrogen.
 5. A compound according to claim 1, wherein A is —CH₂CH₂—.
 6. A compound according to claim 1, wherein R¹ and R² are independently hydrogen or methyl.
 7. A compound according to claim 1, wherein R³ is hydrogen or C₁-C₄ alkyl.
 8. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
 9. A method for treating a disease in a subject comprising: administering to a subject an effective amount of a compound according to claim 1; wherein the disease comprises eye disease.
 10. The method of claim 9, wherein the eye disease comprises glaucoma or a neurodegenerative eye disease.
 11. A method of modulating kinase activity comprising: contacting a cell with a compound according to claim 1 in an amount effective to modulate kinase activity.
 12. The method of claim 11, wherein the cell is in a subject.
 13. A method of reducing intraocular pressure comprising: contacting a cell with a compound according to claim 1 in an amount effective to reduce intraocular pressure.
 14. The method of claim 13, wherein the cell is in a subject. 